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Abstract
Giardia lamblia, a protozoan parasite, is a major cause of waterborne infection, worldwide. While
the trophozoite form of this parasite induces pathological symptoms in the gut, the cyst forms
transmit the infection via contaminated water. Since Giardia is a non-invasive parasite, the actual
mechanism by which it causes infection remains elusive. We have previously reported that Giardia
assembles cholesterol and GM1 glycolipid-enriched lipid rafts (LRs) that participate in encystation
and cyst production. To further delineate the role of LRs in pathogenesis, we isolated LRs from
Giardia and subjected them to proteomic analysis. Various cellular proteins including the virulent
proteins—e.g., giardins, variant surface proteins (VSPs), arginine deaminases (ADAs), elongation
factors (EFs), ornithine carmoyltransferases (OTCs) and high cysteine-rich membrane proteins
(HCMPs)—were found to be present in LRs. Since Giardia secretes virulent proteins (secretome)
encapsulated in extracellular vesicles that induce proinflammatory responses in hosts, vesicles
released by the parasite were isolated and subjected to nanoparticle tracking and proteomic
analyses. Two types of vesicles—i.e., exosome-like small vesicles (SVs; <100nm) and
microvesicles-like large vesicles (LVs; 100–400 nm)—were identified and found to contain
diverse group of proteins including the virulent proteins. Pretreatment of the parasite with two
giardial LRs disruptors, nystatin (27 µM) and oseltamivir (20 µM), altered the expression profiles
of virulent proteins in LVs and SVs, however the effects were more robust in case of SVs. To
examine the potential role of rafts and vesicles in pathogenicity, Giardia-infected mice were
treated with oseltamivir (1.5 mg/kg and 3.0 mg/kg) and the shedding of cysts were monitored. It
was observed that this drug was significantly effective in reducing the parasite load in mice. My
results suggest that virulent factors accumulated in gLRs and secretes via SVs and LVs participate
in spreading giardiasis and could be targeted for drug development in the future. I have proposed
two Specific Aims in my dissertation. In Aim-1, I have proposed to determine if the lipid rafts and
vesicles share proteins including the virulent proteins of Giardia. The goal of Specific Aim-2 is to
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examine if raft disintegrating compounds and their derivatives can be used as potential anti-giardial
agents.
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Chapter 1: Background and Introduction
1.1. GIARDIASIS
Giardia lamblia is an intestinal parasite that affects an estimated 1.2 million people in the United
States1,2 and an estimated 280 million, worldwide.3
The waterborne infection or “giardiasis” is acquired
through the ingestion of contaminated food or water
containing infective cysts. It has also been reported
that pets can be reservoirs for this intestinal parasite.
Studies from Portugal, India, and the United States
reveal this is a growing issue along with a variety of
other parasites and could put owners and families at
risk to obtain this zoonotic infection.4–6 When the
cysts reach the stomach they undergo excystation
triggered by stomach acid.7 The emerging excyzoite
(i.e., newly excysted or emerging trophozoites)
colonize the small intestine and adhere onto the

Figure 1.1: The life cycle of
Giardia. Adapted from the CDC
website(https://www.cdc.gov/dpdx/
giardias is/index.html.)

intestinal epithelium (below the bile duct) with the help of the ventral (adhesive) disc.8,9 In the
small intestine, they form the water-resistant cysts that are excreted though fecal materials and
infect a new host, and thereby completing the life cycle as seen in Figure 1.1.
Giardia has been suggested to have coevolved with its hosts since it has morphological
and genetic differences depending on the species infected.10,11 There are multiple genetic
assemblages that only affect particular hosts, for example livestock is known to be affected by
assemblage E, but they may also harbor assemblage A which affects humans.12 Their ability to
infect cattle also puts an economic strain on many farmers that can suffer thousands of dollars in
damages.12 In addition to this, the intestinal parasite is evolutionarily of great interest since it is
considered as one of the first eukaryotes and is used as a model system.11 To add to their distinct
1

characteristics, they lack mitochondria and peroxisomes, but instead have mitosomes which may
have similar functionalities to the mitochondria.13 A greater characterization of molecular
machinery is needed to show biochemical processes such as vesicular secretion, energy
production, or membrane compartmentalization.
Recent discoveries have shown the importance of cholesterol in lipid raft microdomains.14
Compounds such as oseltamivir and nystatin appear to change cholesterol localizations, and by
extension their membranes and raft domains. Further analysis on how these lipid raft disruptors
affect cell molecular function and structure can be used to elucidate potential therapeutic
compounds against giardiasis.

1.2.LIPID RAFTS
There is an abundant presence of phospholipids on the membrane, which can create saturated
domains that allow for membrane compartmentalization. In addition to this further rigidity of these

Figure 1.2: Highly dynamic lipid rafts and their overall contents.
domains is fortified by high abundances of cholesterol. Lipid rafts (LRs) are microdomains in
membranes that are enriched in sterol and sphingolipids (SLs) as seen in figure 1.2.15 These
domains can vary in size from 10-200 nm.15 Rafts in mammalian cells are also characterized by
2

their sequestration of unique proteins such as glycosylphosphatidylinositol (GPI)

anchored

proteins,16 Src-family tyrosine kinases,17 palmitoylated and myristoylated proteins,18 cholesterol
binding proteins,19 hedgehog proteins,20 heterotrimeric G proteins, and phospholipid-binding
proteins.21 Lipid rafts (LRs) are constantly being disassembled and formed, showing their highly
dynamic structure. This is necessary since they participate in signal transduction, protein complex
formation, membrane transport, and structural integrity. Some examples include immunoglobin E
in allergic responses,22–24 T-cell antigen receptor signaling.

25,26

Ras signaling,27 and glial cell

derived neurotrophic factor signaling.28 Lipid rafts in Giardia are known to be enriched in
cholesterol and GM1 gangliosides.14
Although mammalian LRs are composed of many proteins, it is not known the types of
proteins that are present in giardial LRs. Using Triton X-100 (a non-ionic detergent), followed by
extractions and density-gradient centrifugation it was possible to isolate LRs from Giardia. The
proteins were identified by mass spectrometric analysis and discussed in preliminary results below.
We are interested in seeing how disrupting lipid rafts affects other classes of vesicles, such
extracellular vesicles.
1.3. EXTRA CELLULAR VESICLES
Analysis of vesicle cargo is a recent breakthrough
that has allowed for novel uses such as drug
targeting,29 biomarker analysis,30 advancements in
understanding host modulation31 and even how
bacteria and parasites use them advantageously for
their own propagation.32 There are three types of

Figure 1.3: Illustrates the release of
extracellular vesicles, each emanating from different vesicles and secretome from Giardia that
have pathogenic factors that modulate host
places including the plasma membranes and with response.
varying sizes. Exosomes (40-150 nm) are originated
3

from multi-vesicular bodies in cytoplasm released after fusion of the with the plasma membrane.33–
35

Microvesicles (100-1000 nm) are larger than exosomes.34 They bud directly from the plasma

membrane using a plethora of proteins involved in the endosomal sorting complex required for
transport (ESCRT) dependent and independent pathways.36–38 Finally, there are apoptotic bodies
ranging 500-2000 nm in size that emerge from apoptotic cells.39,40 During giardial replication there
is a release of EVs that assist with attachment and immune modulation.41 Many potential
virulence factors are present in these vesicles such as arginine metabolizing enzymes(AMEs),
ornithine carbamoyl transferases (OCT), enolases, elongation factor 1(EF1), giardins, high
cysteine membrane proteins(HCMPs) and variant surface proteins(VSPs).41–47 It has been shown
that disruption of the lipid rafts affects the EV formation due to depletion of cholesterol on the
membrane.41 However the relationship between lipid rafts and the EVs requires further
investigation. Lipid rafts contain transmembrane proteins from vesicle deposits. However, the
mechanism in which Giardia transports vesicular cargo to the membrane is not well elucidated. In
addition, Giardia’s mechanism of vesicle secretion contains multiple differences compared to
other eukaryotes.48,49 However, there is evidence arguing that the vesicle secretion could be a key
regulator for cyst formation.50
1.4. DRUG TARGETS (LIPID RAFT DISRUPTORS)
Targeting lipid rafts could be potential options for designing therapies against various
diseases.51 For instances, docosahexaenoic acid (DHA) has been employed to inhibit cancer cells
by a reducing EGFR (epidermal growth factor) in raft microdomains.52 Cholesterol disruption of
macrophage membranes using MBCD (methyl- cyclodextrin), nystatin, filipin complexes and
lovastatin, shown to inhibit HIV entry and reverse transcription of the virus.53 Inhibitory effects of
MBCD on SARS-CoV-2 was helpful in identifying additional therapeutic agents (LR inhibitors)
in controlling COVID-19 pandemic.54–56 Therefore, targeting LR domain could serve as critical
sites for developing new therapies, and here we propose to use LR disruptors to treat giardiasis.
4

Currently, the major drugs used to treat giardiasis are metronidazole, tinidazole and
nitazoxanide.57,58 These drugs however have debilitating side effects such as neuropathy and
seizues59 and thus requires further optimization of treatments. On top of this, there is an emerging
issue with drug resistant Giardia for repeated use of metronidazole with high doses in endemic
areas.60–62 We have previously reported that an FDA-approved drug, called oseltamivir (Tamiflu®)
inhibited encystation by disassembling the membrane rafts of this parasite.14 Drug repurposing of
FDA approved compounds is advantageous since they do not need to go through pre-clinical trials
and are safe to use in humans with minimum toxicity. Previous experiments have screened multiple
FDA approved compounds and identified potential targets such as auranofin which has been shown
to be efficacious against giardiasis.63
Oseltamivir free acid (OFA), a derivative of Tamiflu® also known as Imp C (Sigma),
produced by the hydrolysis of its ester moiety was found to be ~5-fold more potent than Tamiflu®
against Giardia cyst formation as well as a potent inhibitor of trophozoite growth with EC50 = 20
μM in culture (Supplement 1, shows the effect of oseltamivir and OFA derivatives on trophozoite
inhibition). This is significant because (i) it demonstrates that further optimization of oseltamivir
classes of compounds are possible; (ii) because OFA belongs to different classes of compounds
than known treatments for giardiasis, OFA and its analogues should be active against
metronidazole-resistant strains; and finally (iii) OFA has poor oral availability64 and thus should
generate minimum systemic toxicity The overall focus therefore is testing additional OFA
derivatives and their effects on lipid rafts assembly and vesicles secreted by Giardia.
1.5.FOCUS OF THE DISSERTATION
Because the incidence of the drug (Mtz)-resistance giardiasis is on the rise, it is important
to identify new targets for designing anti-giardial agents that would be active against the drugresistant Giardia. The current focus of my study is to determine the size and composition of LRs
and EVs from the intestinal parasite Giardia lamblia. In addition, we would like to investigate if
5

LRs and EVs are inter-linked and participate in overall giardial pathogenesis. Because many
proteins are shared between LRs and released EVs, we isolated exosomal/microsomal vesicles
released by the parasite and evaluate their protein profile. The analysis of both composition and
distribution will help to elucidate if the raft-like micro domains and vesicles released by Giardia
are interlinked and if their coordinated functions facilitate the pathogenesis by this waterborne
pathogen. By using LR disruptors, we analyzed the size and compositional changes of rafts and
vesicles, which could be used as potential drug candidates in the future. It is anticipated that results
shown in my dissertation should establish a mechanism by which Giardia, a non-invasive
pathogen, can induce proinflammatory reactions in host epithelial cells.
1.6. SPECIFIC AIMS
The goal of the project is to test the possibility whether lipid rafts (LRs) and EVs can be
targeted for developing anti-giardial therapies.
Giardia lamblia, an intestinal protozoan is responsible for waterborne illness or
“giardiasis” worldwide. This parasite exists in two morphologic forms—i.e., replicative
trophozoites and dormant but viable cysts. Exposure of osmotically resistant cysts to gastric acid
during passage through the human stomach triggers excystation (transformation from cysts to
trophozoites) and factors in the small intestine (in the duodenum and jejunum) where trophozoites
colonize to induce encystation (i.e., differentiation from trophozoites to cysts). We found that
Giardia has the ability to assemble LRs and its disassembly by nystatin (an antifungal agent) and
oseltamivir (Tamiflu®, anti-H1N1 flu) inhibited encystation and cyst production in culture. These
two drugs also interfered with the release of vesicles from Giardia and altered their sizes,
implicating that repurposing and rational drug designing against Giardia is a possibility. Results
also indicate both LRs and released vesicles are interlinked, share common proteins, and involved
in giardial pathogenicity.

6

I hypothesize that the rafts-like micro domains and vesicles released by Giardia contains
virulent proteins these proteins mount immune responses in host intestinal epithelial cells
producing diarrhea-like symptoms and illness. I also hypothesize that LRs and vesicles
disassembly drugs can be used as anti-giardial therapy in the future. Therefore, the Specific Aims
are:

Aim 1: Determine if the lipid rafts and vesicles share common proteins and facilitate the
process of giardial pathogenesis.
● Isolate and characterize LRs and secreted vesicles from Giardia
● Determining proteome profile of rafts and secreted vesicles
● Evaluate the effects of nystatin and oseltamivir on rafts and vesicles assembly
Aim 2: Determine that rafts and vesicles disassembly drugs can be used as anti-giardial
therapies.
● Test oseltamivir on the assembly of rafts and vesicles.
● Evaluate effective drugs in a pre-clinical model.

7

Chapter 2: Lipid Rafts: Isolation, Characterization and Proteomic Analysis

2.1 MATERIALS AND METHODS

Materials
All chemicals used in this investigation were purchased from Sigma-Aldrich (St. Louis,
MO). Solvents and reagents used for mass spectrometry were of LC/MS grade (Fisher Chemical).
Adult bovine serum (catalogue no. SH30075.03) was obtained from Hyclone Laboratory (Utah).
Cyst antibody was purchased from Santa Cruz (Santa Cruz, CA) and Invitrogen (Carlsbad, CA),
respectively. Lipid raft labeling kit (Vybrant Alexa Fluor 488, V34403) and were purchased from
Invitrogen (Carlsbad, CA). Nystatin was obtained from Sigma-Aldrich Co., LLC (St. Louis, MO).
Oseltamivir (Tamiflu®) and myriocin were purchased from Selleckchem (Houston, TX) and
Sigma-Aldrich, respectively. CaCo-2 cell lines were obtained from the ATCC.
Cell Culture
Giardia lamblia trophozoites assemblage A (strain WB C6; ATCC No. 30957) and
assemblage B (strain GS H7; ATCC 50581) were cultivated following the method of Diamond et
al (1978)65 using modified TYI-S-33 medium supplemented with 10% adult bovine serum and 0.5
mg/ml bovine bile.66,67 The antibiotic piperacillin (100µg/ml) was added during routine culturing
of the parasite.68 The growth was initiated by adding ∼105 trophozoites/ml in the culture medium
and continued to grow until the cells became 80–90% confluent (∼48 h). To produce cysts,
trophozoites from WB isolates were cultured in high bile medium as previously described by
Keister et al.66 The trophozoites and cysts forms of human Giardia isolate H3 (assemblage Bcollected from gerbils), were purchased from the Waterborne Inc. (New Orleans), LA. Caco-2
cells were obtained from the ATCC.

8

Identification and Isolation of Lipid Rafts
Lipid rafts (LRs) in
Giardia

trophozoites and

cysts were identified by
immunostaining

with

cholera toxin B (CTXB) and
GM1 antibody. Briefly, cells
were

harvested

by

centrifugation, washed in
PBS and stained with cholera
toxin B (CTXB) or GM1
Figure 2.1: Demonstrates the Lipid Raft clean up and
quantitation methodologies that are run to analyze size and
composition

antibody as described earlier
(De Chatterjee et al. 2015).
For CTXB labeling, 1x107

cells (trophozoites and cysts) were fixed in 4% formaldehyde followed by immunostaining with
CTXB conjugated to Alexa Fluor 488 (1 g/ml) for 10 min before reacting with CTXB antibody
(1:200 dilution) for 15 min as recommended by the manufacturer. Lipid rafts (LRs) were also
immunostained with GM1 antibody. For this, cells were incubated GM1 antibody (1:50 dilution)
for overnight in cold and then with a secondary antibody conjugated to Alexa Fluor 568 (1:500
dilution) for 1 h. Both CTXB- and GM1- labeled cells were mounted with ProLong Gold antifade
reagent with DAPI (Invitrogen) and visualized by confocal microscopy (Carl Zeiss LSM 700
confocal microscope).
Lipid rafts from Giardia was isolated following the method described by De Chatterjee et
al. (2015).14 Briefly, ~1x109 trophozoites collected from the TYI-S-33 growth medium, washed in
PBS and incubated with HRP-conjugated CTXB for 1 h at 4oC.69,70 Trophozoites were was and
resuspended in 5 mM Tris-HCl buffer (pH 7.8) containing EDTA (2 mM), DTT (0.4 mM), Triton
9

X-100 (1%) and protease inhibitors. Lysate was placed at the bottom Optiprep™ density gradient
(35%, 30%, 25%, 20% and 0%). Samples were centrifuged at 200,000 x g for 4h with a Sorvall T865.1 fixed-angle rotor (Sorvall WX Ultra series centrifuge; Thermo Scientific, IL). Fractions of
1ml were collected from top of the gradient and the HRP-CTXB enriched LR fractions were
identified by ELISA assay. To investigate if LR fractions were enriched in cholesterol and GM1,
cholesterol measurement kit (Invitrogen) and GM1 antibody-based ELISA assays were employed
as described earier14. Cholesterol and GM1 enriched LR fractions were subjected proteomic
analysis as described below.
Transmission electron microscopy (TEM)
For ultrastructural analyses, samples were fixed in 2% paraformaldehyde/2.5%
glutaraldehyde in 100 mM sodium cacodylate buffer for 2 h at room temperature. Samples were
washed in sodium cacodylate buffer, embedded in 2.5% agarose, and postfixed in 2% osmium
tetroxide (Ted Pella Inc, Redding, CA) for 1 h at room temperature. After three washed in dH2O,
samples were en bloc stained in 1% aqueous uranyl acetate (Electron Microscopy Sciences,
Hatfield, PA) for 1 h. Samples were then rinsed in dH20, dehydrated in a graded series of ethanol,
and embedded in Eponate 12 resin (Ted Pella Inc). Sections of 95 nm were cut with a Leica
Ultracut UCT ultramicrotome (Leica Microsystems Inc., Bannockburn, IL), stained with uranyl
acetate and lead citrate, and viewed on a JEOL 1200 EX transmission electron microscope (JEOL
USA Inc., Peabody, MA) equipped with an AMT 8-megapixel digital camera and AMT Image
Capture Engine V602 software (Advanced Microscopy Techniques, Woburn, MA).
dSTORM Microscopy
Giardia trophozoites were fixed with 4 % PFA at 4°C for 10 min before being probed,
followed by vigorous washing. For GM1 labeling, 3x106 cells/ml were stained at 4°C for 10 min
with 1:1000 CTxB-AF647 conjugate (Thermo Fisher Scientific, C34778), then washed three times
10

with chilled PBS followed by centrifugation (800RCF) at 4°C for 5 min. The cells were then
treated for 15 minutes at 4°C with a 1:200 dilution of anti-CTXB, 1% Normal Goat Serum. For 5
min cells were washed three times with chilled PBS at 800RCF (4°C). To limit motion during
acquisition, samples were embedded in 4% low gelling temperature agarose (Sigma Aldrich,
A9414) on a coverslip prior to imaging
dSTORM Imaging
The following protocols were obtained from Villalobos et. al.71 Image methods were
duplicated from Neumann et. al.72 For more information on algorithm deconvolution and image
reconstruction the reference of Neumann et. al.72 was followed.
NanoSight Methodology
Model LM14C (Malvern) of the NanoSight was used to quantify the number of vesicles
per sample. Samples were diluted by 1/10 in triple filtered PBS. Software NTA 2.2 build 0377 was
used for the analysis. The following are the settings used for the analysis: background extract: on,
gain: 1, blur size: auto, detection threshold type: multi, detection threshold: 10, temperature (°C):
22, duration: 60s.

Protein concentration and Tryptic digestion
Sample protein concentrations were measured by Bicinchoninic acid assay (BCA)
according to manufacturer instructions (Pierce

TM

BCA Protein Assay kit, cat no. 23227). After

protein concentration acquisition was performed in the BioTek Cytation5 plate reader, 100 µg of
each protein sample obtained from the step was used for protein digestion by a modified method
(FASP Protein Digestion Expedeon, cat no. 44250), using trypsin (Sigma, cat no.T6567) to obtain
peptides for analyses by mass spectrometry. Next, 200 µl of 12.48 M urea solution containing 100
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mM Tris-HCl pH 8.0 (urea solution) was mixed with 100 µg of each protein sample and10 mM of
DL-Dithiothreitol (Sigma, Cat no. D0632-5G) was added to each sample to reduce the disulfide
bonds of proteins. Samples were vortexed and placed in a nutating mixer for 45 minutes at room
temperature. Samples were then transferred to a 30 KD filter and centrifuged for 15 min at 14,000
rpm. An amount of 200 µl of urea solution was added to each spin filter and centrifuged at 14,000
rpm for 15 min and this step was repeated. Flow through was discarded right after centrifugation.
A 100 mM iodoacetamide solution (10× IOD) was prepared by resuspending IOD in 100ul of urea
solution. A solution of 1× IOD was prepared (1:10 ratio in urea solution) and 100 µl of 1× IOD
was added to each spin filter and samples were incubated for 20 min in the dark. After dark
incubation, spin filters were centrifuged at 14,000 rpm for 10 min. Spin filters were washed twice
with 100 µl of urea solution. To remove urea from the samples, 100 µl of 50 mM ammonium
bicarbonate solution was added to spin filter and centrifuged at 14,000 rpm for 15 min. This step
was repeated twice (total of three times). Spin filters were transferred to new spin filter tubes and
100 µl of trypsin digestion solution at 1:50 enzyme: protein ratio was added to each sample and
incubated at 37ºC overnight, for 16 hours. Then, 200 µl of 0.1% formic acid LC/MS grade water
solution was added to each sample and spin filters were centrifuged at 14,000 rpm for 10 min for
elution of peptides. Resulting tryptic peptides were frozen at -80 ºC for two hours and subsequently
dried in a lyophilizer. Samples were re-suspended with 100 µl of 0.1% formic acid LCMC grade
water solution for a final concentration of 1µg/µl prior to 1D LC-MS/MS analysis.
Mass Spectrometry Methodology
All experiments were carried out with a U300 Q-Executive mass spectrometer and
Ultimate 3000 RS HPLC System. A 10 h 5 step 2d-LC-MS/MS method was run with 5 μl injections
of ammonium acetate from the auto sampler (100, 250, 500, 750, 1000 mM). One hundred fifty
micromolar fused silica was used and packed with 5 cm of SCX material (Luna). Instrumental
conditions used: top 10, runtime: 120min, default charge state: 2, resolution: 70,000, AGC target:
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3e6, maximum IT: 100ms, scan range 400 to 1600 m/z, for dd-MS2 resolution: 17,500, AGC target
1e5, maximum IT: 50ms, Minimum AGC target: 8e3, dynamic exclusion: 15s. Solvent A was 95%
acetonitrile, 5% water, 0.01% formic acid. Solvent B was 5% water, 95% acetonitrile, 0.01%
formic acid. Solvent C was 500 mM ammonium acetate in solvent A. Run gradients was (t=05min,

5%

B;

t=5-5.1min,

per

pulse

[20%,40%,60%,80%,100%]

C;

t=5.1-7.5min,

[20%,40%,60%,80%,100%]C; t=7.5-8min,5%B; t=8-15min,5%B; t=15-120min, 50%B). Wash
gradient was (t=0-5min, 5% B; t=5-20min, 95% B; t=20-22min, 5%B; t=22-25min, 5%B; t=2540min, 95%B; t=40-42min, 5%B; t=42-60min, 5%) with a flow rate of 300 μl/min. It should be
noted that in the first 10 minutes of the 120 min method no charge was applied to the mass
spectrometer. This was to prevent ammonium acetate from flowing into the mass spectrometer,
which would lower its performance. During the first ten minutes the salt pulse allows the peptides
to flow from the SCX column to the C18 front column and then Solvent A washes the tip before
the voltage is applied again. The wash can be extended depending on the amount of salt is being
used in the method.
Bioinformatics
Proteome Discover (PD) 2.5.0.400 (Thermo Fisher) was utilized to ID the proteins from
peptide mixtures. Database for Giardia was downloaded from UniProtKB; http://www.uniprot.org/
on 21 April 2021 with a database 30,894 sequences. A contaminant dataset was run in parallel
compose of trypsin autolysis fragments, keratins, standards found in CRAPome repository and inhouse contaminants. PD analysis parameters are as follows: false-discovery rate (FDR) of 1%,
HCD MS/MS, fully tryptic peptides only, up to 2 missed cleavages, parent-ion mass of 10 ppm
(monoisotopic); fragment mass tolerance of 0.6 Da (in Sequest) and 0.02 Da (in PD 2.1.1.21)
(monoisotopic). Two-high confidence peptides per protein were applied for identifications. PD
dataset was processed through Scaffold Q+ 4.8.2 (Proteome Software, Portland, OR) for protein
quantification. A protein threshold of 99%, peptide threshold of 95%, and a minimum number of
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2 peptides were used for protein validation. PCA analysis were carried out using Perseus
(MaxQuant)73 and Venn diagrams we created using FunRich 3.1.4.74–76
Statistical Analysis
Statistical analysis of the data was executed with GraphPad Prism 9.2.0. Values are
represented as means ± standard deviation (SD). NanoSight data had a minimum of three
biological replicates and an ns = 3 per NanoSight run. Proteomic statistics were acquired through
both Scaffold LFQ 4.0.2 and GraphPad Prism. LR extractions contain an ns = 2 with ns = 3 per
sample and a ns = 5 per fraction in MS/MS analysis. The normality of the data was evaluated using
Shapiro-Wilk test and statistical analysis were acquired through students T-test. Samples that had
a p-value ≤ .05 were considered significant.

2.2 RESULTS

Organization and size determination of lipid rafts in Giardia
Because of their dynamic nature, the size of lipid rafts (LRs) in eukaryotic cells can vary
from 10-200 m.78 Since Giardia is a primitive eukaryote and LRs in participate in encystation
and cyst production,14 it was our interest to determine the organization and size of these
microdomains in this parasite. Figure 2.2 demonstrates the immunostaining of rafts in Giardia
with Alexa Fluor 488-conjugated CTXB (green) and GM1 antibody (red). CTXB and GM1
antibody binds with GM1 (mono-sialoganglioside) in LRs.77,78 In trophozoites, LRs are mostly
localized in plasma membranes and appears as punctate structures (panel A). LRs are also present
in the plasma membranes of water-resistant cysts. The immunostaining of cysts with CTXB
(green) and cyst-wall protein (CWP) antibody (conjugated to Alexa Fluor) shows green colored
14

plasma membranes of cysts beneath the cyst walls (red) of Giardia. In trophozoite of WB isolate,
the staining of ventral disk and punctate structures of plasma are clearly visible. Rafts are also
present in GS and H3 isolates of Giardia implicating the abundance of membrane microdomains
in assemblages A and B (human assemblages). Interestingly, they all show the characteristic
punctate structures of rafts in plasma membranes of trophozoites. In panel B, we used Structured
Illumination Microscopy (SIM) to visualize LRs in higher resolution.79 The measurements
obtained from the CTXB staining show a very close approximation varying from 124 nm to
224nm.80
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Figure 2.2: Panel A. Staining of lipid rafts in WB, GS and H3. Trophozoites were labeled with
Alexa Fluor (488)-conjugated CTXB (images a, c and e) and GM1 antibody (image d)
Immunostaining of raft domains in plasma membranes, the ventral disc, and the flagella of
trophozoites is visible. DAPI-stained nuclei are also visible. The image of CTXB-labeled Giardia
trophozoites and cysts (images b, f) were captured with the help of Zen 2009 software. Z-stacks
were acquired, and a 3D model was reconstructed from the 12 optical sections of the z-stacks with
a slice thickness of 0.37 μm each. Bars, 5 μm. (B) 3D representation. The image of CTXB-labeled
Giardia trophozoites was captured using Zen 2009 software. Z-stacks were acquired, and a 3D
model was reconstructed from the 12 optical sections of the z-stacks with a slice thickness of 0.37
μm each.

To further determine the size and structure of giardial rafts, we employed the single
molecular localization-based super-resolution microscopy. More specifically an analysis was done
with direct stochastic optical reconstruction microscopy (dSTORM). Single-molecule based superresolution techniques employ photo switchable fluorophores, single-molecule localization,
temporal separation, and image reconstruction and achieve an optical resolution of down to ~20
nm in the imaging plane.81–84 With dSTORM the molecular radii of giardial labeled rafts (after
staining with GM1 antibody) was measured with a higher precision. It appears (Figure 2.3) that
the mean radii of LRs is approximately19.29 nm. This is significantly smaller compared to SIM
data and may be more indicative of the true lipid raft size.80 Figure 2.4 show staining of GM1 by
CTXB and the overall distribution of raft sizes after treatment with LR disruptors. Giardial cells
were treated with LR disruptors nystatin (27 μM), oseltamivir (20 μM) to see any changes in the
LR size composition. Myriocin (27 μM), an inhibitor of 3-keto-sphinganine synthesis,85 was used
as a nonspecific binding reference. When cells are treated with LR disruptors the overall densities
of GM1 decreased significantly compared to the untreated. When observing the single GM1
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densities we see there is a more apparent change in oseltamivir compared to nystatin. Most
importantly the cluster radius, of oseltamivir and nystatin decreased significantly. This gives
evidence to suggest that treatment with the LR disruptors may affect the distribution of the LR
sizes.

Figure 2.3: Trophozoites were labeled with Alexa Fluor488-conjugated CTXB analyzed with
dSTORM analysis. A total of 15 giardial cells were analyzed with 33 Regions of Interest (ROIs).
Density of multi-lipid exposure, density of singlet exposure and overall mean cluster radii were
conducted. Mean cluster radii are shown to have a mean value of 19.29nm. Bars, 2500nm
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Figure 2.4: Nanoscopic GM1 clustering characteristics. A) Representative dSTORM images of
G. lamblia untreated and treated with various agents. Bars, 2500nm B) Hierarchical clustering
quantification of nanoscopic GM1 cluster geometries for densities of multiple GM1 clusters. C)
Hierarchical clustering quantification of nanoscopic GM1 singlet densities. D) Quantification of
GM1 cluster radii. 15 cells were imaged per sample, and regions of interest (ROI) were selected
on each cell. Each sample ranges from 32-35 total ROIs investigated.

To better visualize the overall effects LR disruptors on the plasma membrane of Giardia,
TEM analysis was carried out as shown in Figure 2.5. When treated with nystatin the giardial
membrane show a discontinuous lipid bilayer. The bilayers appear to have small holes showing
the disruption occurring. Interestingly, in oseltamivir treated cells show a much thinner membrane
compared to the control. In the outer leaflet of the untreated cells, a thick clustering is visible,
which is completely lost after oseltamivir treatment.
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Figure 2.5: TEM analysis of the resin embedded of the giardial inner and outer leaflet membrane
between the control and after treatment with Nystatin (27 μM) and Oseltamivir (20 μM). Arrows
depict holes across the plasma membrane. Bar:

Identifying the cargoes present in LRs is a crucial step for understanding the role of
membrane rafts in giardial pathogenesis. Therefore, LRs were isolated by OptiprepTM-based
density-gradient centrifugation following the methodology previously described by De Chatterjee
et al. and others.86,87, 88,89 Because raft domains are enriched in cholesterol and GM1 glycolipid,
the recovery of raft membranes were monitored by assessing these two markers in each fractions.
It is clear (Figure 2.8) that the LRs are distributed in fractions 2-5 as evidenced by matching with
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the cholesterol and GM1 peaks. The enrichment of LRs in those fractions was also confirmed by
the presence of GP49, a GPI-anchored protein migrated in the insoluble phase of Triton X-100
during the phase separation.90 The pretreatments of Giardia with raft disruptors, nystatin and
oseltamivir were found to alter the separation profile of LR fractions.

Figure 2.6: Isolation of lipid rafts from Giardia trophozoites. (A) Cholesterol-enriched peaks. (B)
GM1 glycolipid-enriched peaks. Cholesterol and GM1-enriched micro domains are likely to be
present in fractions 2-5 (indicated by red bar). The proteomic analysis was conducted with pooled
fractions 3-5
Each LR fraction was analyzed via the nanoparticle tracking system (NanoSight) to
determine their size and evaluate the changes between the treatments as shown in Figure 2.7.
Results demonstrate that there is a shift in size between fractions 3, 4 and 5. The LR size profiles
seem to decrease drastically between fraction 3 and 4 in the treatment groups and decrease in
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fraction 5 when treated with oseltamivir. This further supports the hypothesis that oseltamivir and
nystatin disrupt the raft domains in Giardia.

Figure 2.7: The following shows the lipid rafts processed through NanoSight analysis between
the control, oseltamivir, and nystatin treatments as well as the differences in vesicle composition
between fractions from the sucrose gradient.

Proteomic Analysis of Lipid Raft Fractions
Lipid rafts or microdomains are ordered membrane structures enriched in cholesterol,
glycosphingolipids, and proteins. Although the types and classes of proteins that are abundant in
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mammalian rafts can be retrieved from Raftprot Database V2 (Raftprot.org), no information is
available on giardial raft proteome. In addition, the genes for classical LR markers such as
caveolin, flotinin etc. are not annotated in the Giardia Genome Database (GiardiaDB.org.), we
took an effort to conduct proteomic analysis of giardial LRs. In Figure 2.6, we have shown that
the most abundant fractions containing GM1, and cholesterol are in fractions are 3, 4 and 5. To
conduct the proteomic analysis, I have taken these fractions (control and treated) and run MS/MS
analysis. The Principal Component Analysis (PCA, Figure 2.8) demonstrates that proteomic data
from fractions 3, 4 and 5 cluster together. On the other hand, fraction 7, which is a non-raft fraction,
is partitioned separately.
A general bioinformatic analysis was conducted to evaluate if there were any changes in
proteomic profiles among LR fractions. We looked at the overall proteomic profiles between the
fractions and treatments as well as the general VSPs (variable surface proteins), kinases and high
cysteine containing proteins as seen in Figure 2.9. Relevant to this study the only major change
occurs in fraction 3 having an overall increase in kinase protein abundance. Fraction 7 also has an
overall decrease in kinase abundance between the control and nystatin and an overall decrease in
proteins between the control and oseltamivir. In addition to the general number of proteins found
per group were plotted the expression level of kinases and VSPs between the fractions and
treatments as seen in Figure 2.10. Overall, kinase protein expression levels increase in oseltamivir
in fraction 3 and there is an overall decrease in nystatin and oseltamivir in fraction 5 compared to
the control. VSP protein expression seems to be similar among the fractions with a greater number
of expression tending to be found in fraction 3 overall. In Figure 2.11 we constructed Venn
Diagrams using FunRich v3.1.4 program to represent the overall similarity between the fractions
and between the treatments on each fraction.74 In panel A, the control showing the normal
distribution of proteins among fractions 3, 4, 5 and 7. There are overall significant increases in
protein abundance between comparisons displayed in red circles. Proteins shared between fraction
3 and the other fractions in oseltamivir treatment increase significantly compared to the control as
seen in red circles on the Venn diagram in panel A Figure 2.11. Proteins that show an overall
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decrease compared to the control are shared in fraction 4 in both oseltamivir and nystatin circled
in blue. Nystatin changes are a more variable having protein abundance decrease occur between
fraction 4, 5 and 7.

Figure 2.8: Principal Component Analysis (PCA) illustrates the similarities and differences in
protein profile among control (C), nystatin (N, 27 μM) and Oseltamivir (O, 20 μM) treated cells.
Weighted peptide spectral matches were used when quantifying the overall similarities between
samples.
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Figure 2.9: Differentially expressed proteins groups between Control (C) and treatments with
Nystatin (N, 27 μM) and oseltamivir (O, 20 μM). Comparisons were done between overall protein,
VSP, kinases and cysteine protein groups. Welch’s T-test was applied between mean ± standard
deviation (SD) of triplicate experiments. *p < 0.05, **p < 0.01, ***p <0.001 or ****p<.0001
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Figure 2.10: Comparison of protein expression levels in A) kinases and B) VSP expression
between the three LR fractions during Optiprep differential centrifugation as well as treatments
between Control(C) and treatments with nystatin (N) and oseltamivir (O).
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Figure 2.11: Venn Diagrams comparing the shared proteins between (A) the fractions from the
Optiprep gradient (3,4,5,7) for the control (C) and treatments with nystatin(N) (27 μM) and
oseltamivir(O) (20 μM). (B) the comparison of treatments between the same fractions. Red circles
indicate an increase in protein abundance while blue circles represent a decrease in protein
abundance
To examine the groups of proteins that are differentially affected by nystatin and
oseltamivir treatments, volcano plots were constructed to show the significance changes (log2 fold
changes) as shown in Figure 2.12. A threshold fold change of 1.5 was used as a cut off with a pvalue ≤ .05. Table 2.1.1 and 2.1.2 represent the proteins that were found to be differentially
expressed from the volcano plots which includes their protein name, gene name, p-value and log2
fold change. Table 2.2 represents the combined collective top 10 proteins from each group to
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represent their collective abundance and table 2.3 represents the collective abundance of the top
10 proteins between each fraction to illustrate the proteins that are most abundant in the lipid rafts.

Figure 2.12: Volcano plots of differential protein expressions in control and drug treated lipid
rafts. (A) Control (C) and treatments with nystatin (N) (27 μM). (B) Control and oseltamivir (O)
(20 μM) treatment. Volcano plots show –log10 P-values from the normalized proteomics data
exported from Scaffold LFQ versus log2foldchange (FC) across each contrast. Thresholds set were
p-value ≤ .05 and Log2FC ≤ -1.5 or ≥ 1.5.
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Table 2.1.1 Significant proteins from volcano plot in lipid rafts control v nystatin
LR_C_V_N
Protein names
ABC transporter family protein
Ankyrin repeat protein 1
Ankyrin repeat protein 1 (Protein 21.1)
ARF GAP
Coiled-coil protein
Flap endonuclease 1 (FEN-1) (EC 3.1.-.-) (Flap structure-specific
endonuclease 1)
High cysteine membrane protein Group 1
High cysteine membrane protein Group 1
High cysteine membrane protein Group 1
High cysteine membrane protein Group 2
Kelch repeat-containing protein
Kinase, NEK
Kinesin-related protein
LSU ribosomal protein L10AE
Protein 21.2
Putative Nudix hydrolase
Tenascin (Tenascin-like protein)
Tenascin-37 (Tenascin-like protein)
Triosephosphate isomerase (EC 5.3.1.1) (Fragment)
Tubulin-folding cofactor C
Uncharacterized protein
Uncharacterized protein
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Gene
A8B361
A0A644FBQ8
A8B9H3
E1F0N6
A8BNH0

pvalue
0.0015
0.025
0.0021
0.039
0.019

log2fc
-0.70
-0.91
-0.67
0.64
0.63

A8B672

0.022

-0.94

E1F797
A8BCN1
A8BME9
A8BTH1
E1F4Z8
A8B2B4
A8BC06
V6TJ23
Q967Z9
A8BMV8
A8B2G0
A8B301
A0A1Q1PRU6
A8BEZ7
A8BJB0
V6TJA1

0.032
0.041
0.043
0.037
0.024
0.035
0.048
0.007
0.042
0.018
0.05
0.05
0.01
0.017
0.047
0.031

0.62
0.64
0.95
0.72
0.63
-0.89
-0.98
1.13
-0.66
-0.65
-0.70
-0.63
0.73
-0.82
-0.89
-0.80

Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Zinc finger domain protein (Zinc finger domain-containing protein)

A8BCJ6
A8BFW5
C6LS23
E1EXG0
A8BLF7
A8BWU7
A8BWK6
V6U482
A8BRD6

0.033
0.032
0.01
0.017
0.0067
0.051
0.0032
0.022
0.047

-0.79
-0.76
-0.74
-0.69
-0.63
0.62
0.78
0.89
-0.71

Table 2.1.2 Significant proteins from volcano plot in lipid rafts control v oseltamivir
LR_C_V_O
Protein names
14-3-3 protein
ABC transporter family protein
ABC transporter family protein
ABC transporter, ATP-binding protein
ABC transporter, ATP-binding protein
ABC transporter, putative (Fragment)
Amino acid transporter family
Ankyrin repeat protein 3 (Protein 21.1)
Beta giardin (Fragment)
Beta giardin (Fragment)
Beta-giardin (Fragment)
Beta-giardin (Fragment)
Beta-giardin (Fragment)
Chaperonin 10
Clathrin heavy chain
Clathrin heavy chain
Clathrin heavy chain
GPN-loop GTPase 3
Heat shock protein HSP 90-alpha
HesB domain-containing protein (Iron-sulfur cluster biosynthesis
protein IscA)
Kinase, NEK
Metallo-beta-lactamase superfamily protein
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Gene
E2RU98
A8B361
A8BQT7
C6M0H4
A8B9R4
A8BN72
A8B634
A8B9H1
A0A3G9K8G1
D0QYZ1
B4Y0X1
A0A2I7YW49
A0A1M4M1D5
A8B8M1
A8B515
V6TEI1
V6TZT4
A8BBA2
A8BBJ7

pvalue
0.018
0.0079
0.0054
0.039
0.047
0.031
0.041
0.03
0.039
0.03
0.031
0.013
0.033
0.041
0.025
0.016
0.035
0.052
0.024

log2fc
0.67
-0.99
-0.82
-1.36
-0.96
-1.15
-0.70
0.99
0.60
0.70
0.74
0.75
0.80
1.01
-0.85
-0.82
-0.76
0.67
0.62

A8BCH8

0.013

-0.61

C6LY62
A8BBV2

0.037
0.036

0.62
0.80

Methionine adenosyltransferase (EC 2.5.1.6)
Mitogen-activated protein kinase (EC 2.7.11.24)
MRP-like ABC transporter
Multidrug resistance-associated protein 1
Nucleotidyl cyclase
Nucleotidyl cyclase
Peptidylprolyl isomerase (EC 5.2.1.8)
Phospholipid-translocating P-type ATPase (Flippase)
Uncharacterized protein
Potassium-transporting ATPase alpha chain 1 (EC 3.6.3.10)
(Sodium/potassium-transporting ATPase subunit alpha)
Potassium-transporting ATPase alpha chain 1 (Fragment)
PPPDE putative peptidase domain-containing protein
Proliferating cell nuclear antigen
Protein 21.1
Putative Phospholipid-transporting ATPase IIB
Putative WD-repeat family protein
Qb-SNARE 4
Sec7 family protein
Sodium or proton/potassium antiporter, ATPase alpha subunit
Suppressor of actin 1
Synaptic glycoprotein SC2
Tenascin-like protein
Thioredoxin reductase (EC 1.8.1.9)
TMP 52
Translation elongation factor (Translation elongation factor 1beta)
Translation initiation factor
Triosephosphate isomerase (EC 5.3.1.1) (Fragment)
Ubiquitin-conjugating enzyme E2
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
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V6THV5
E2RTU0
A8B476
A8B3T0
A8B947
V6TIL2
A8BAF3
V6TRQ7
A8BCP4

0.032
0.053
0.019
0.011
0.045
0.053
0.011
0.007
0.044

0.95
0.80
-0.92
-0.86
-0.96
-0.75
0.69
-0.69
-0.64

A8BV45

0.0079

-0.71

E1F8Y8
A0A644F9E9
A8BIU1
E1F6M7
A0A644F1Y5
V6TJF3
A8B2J8
A8BK70
V6TA72
A8BB34
A8BNY7
A8BDS8
Q8IFV3
Q95WV6

0.014
0.02
0.043
0.045
0.025
0.00053
0.053
0.026
0.0066
0.03
0.031
0.025
0.013
0.0063

-0.90
0.66
0.60
0.77
-0.93
0.76
-0.78
-1.10
-0.71
-0.66
-0.75
0.88
0.65
-0.67

A8BZ22

0.012

0.77

V6TLS8
A0A1Q1PRU6
V6TGB1
E1F8F5
A8BK53
A8BQI8
V6TFG9
A0A644F557
A8B4M7
A8BLW9
V6TCW1
V6U482
A8BTM8
A8BWK6
V6TB36

0.0083
0.032
0.018
0.011
0.036
0.044
0.046
0.044
0.048
0.03
0.002
0.023
0.015
0.021
0.01

0.96
0.95
0.76
-1.32
-1.07
-1.04
-0.79
-0.77
0.62
0.62
0.65
0.80
0.84
0.92
1.04

A8BTN1
A8BJ72
A8BGB4

Uncharacterized protein
Vacuolar protein sorting 11
V-type proton ATPase subunit a
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0.003
0.026
0.045

1.10
-1.13
-0.83

Table 2.2 Combined Top 10 Proteins in LR and Treatments
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Table 2.3 Top 10 proteins found in Lipid Rafts Control Only

Protein Name

Accession
Number

A8BB85
Carbamate kinase OS
Group of Tubulin
V6TQK6 (+1)
alpha chain OS
Uncharacterized
A8BL74
protein OS
Ornithine
carbamoyltransferase
O76458
OS
Tubulin beta chain
V6TBM5
OS
Pyruvate, phosphate
Q27662
dikinase OS
V6TVY8
Carbamate kinase OS
A8BYC4
Peroxiredoxin 1 OS
Elongation factor 1Q08046
alpha (Fragment) OS
Fructosebisphosphate
V6TLE8
aldolase OS
A8BH19
Kinase, NEK OS
A8BCR6
Cytosolic HSP70 OS
Q4VPP2
Alpha-11 giardin OS
Ornithine
carbamoyltransferase
E1EZW7
OS
Axoneme-associated
A8BBT5
protein GASP-180 OS
Axoneme-associated
Q962Q0
protein GASP-180 OS
E2RU98
14-3-3 protein OS
Axoneme-associated
A8B5G1
protein GASP-180 OS
A8BH24
Kinase, NEK OS
E2RU57
Alpha-7.3 giardin OS
A8BAF5
Coiled-coil protein OS
A0A644F364
VSP with INR OS
Q95VP0
Alpha-3 giardin OS

Molecular
Weight

C3_1

C3_2

34 kDa

251.87

271.44

256.88 197.18 224.12

449.23

230.32

180.96

296.49 220.58 262.42

382.46

43 kDa

79.99

247.34

264.83 261.40 492.42

347.76

36 kDa

577.49

422.80

188.16 229.81 231.36

297.12

51 kDa

385.75

373.76

246.48 316.22 267.85

289.52

98 kDa

250.17

197.87

192.66 257.82 271.17

270.21

39 kDa
23 kDa

51.06
180.40

73.57
119.23

160.25
65.12

121.56
117.03

256.38
256.01

44 kDa

54.46

172.50

190.16 184.61 290.27

244.18

35 kDa

207.63

167.43

411.73 307.47 233.47

241.44

57 kDa
72 kDa
35 kDa

1085.21 1328.03 317.65 386.96 430.28
282.51 248.61 233.47 278.82 304.05
420.36 560.64 302.79 341.37 139.36

188.30
185.37
177.90

36 kDa

427.73

240.15

116.14 149.60 170.42

139.78

116 kDa

378.94

240.15

178.46 190.34 101.65

108.76

179 kDa

110.28

194.83

238.77 297.98 311.53

106.50

29 kDa

173.59

91.33

266.48 299.83 246.13

98.67

175 kDa

100.07

177.07

206.46 261.30 261.06

97.91

78 kDa
33 kDa
191 kDa
73 kDa
33 kDa

435.67 593.62 108.63 139.41 63.95
1670.87 1491.35 149.01 168.08 69.82
1181.08 913.26 406.33 432.08 174.95
188.34 641.82 205.75 296.52 270.68
336.97 345.01 80.43 93.10 28.96

75.50
75.03
43.73
31.02
22.80
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C4_1

C4_2

74.00
79.25

C5_1

C5_2

Uncharacterized
protein OS

V6T9H5

33 kDa

427.05

35

461.07

81.61

79.09

38.87

19.90

Chapter 3: Extracellular Vesicles: Isolation, Characterization and Proteomic Analysis
3.1 VESICLE ISOLATION AND METHODOLOGIES
Two separate methodologies for vesicles isolation were conducted. And they are: (1) Sizeexclusion chromatography and (2) Differential centrifugation.
Size Exclusion Chromatography
Wild type (WB C6)
cells and overexpressed with
variant surface protein (called
TSA417) cells were grown to
confluency in a T-25 flask
containing TY-I-S33 (pH 7.1)
medium supplemented with
1% bovine bile and 5% adult
bovine serum. Approximately
1 x 107 were harvested via ice
chill, then the cells were
Figure 3.1: Vesicle Isolation through size exclusion
chromatography and quantitation methodologies that are run to
analyze size and composition.

pelleted by centrifugation at
2400 x g for 5 minutes at 4°C.
For treatment, cells were

resuspended in TYI-S-33 medium without serum and incubated with nystatin (27 μM), oseltamivir
(20 μM), and OFA (oseltamivir-free acid; 10 μM) for 30 min at 37oC. After the incubation, the
cells were collected by centrifugation (2400 x g) and the supernatant was discarded. The cells were
washed three times using 3x filtered 1x PBS before placing them (~1x107) in 4 ml vials containing
PBS supplemented with 5mM L-cysteine, 5mM glucose, and 1mM CaCl2 (pH of 7.1) for 6 hours
at 37°C to allow for the vesicle secretion. The cell viability was assessed by flow cytometry after
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staining with propidium iodide (PI). Figure 3.3 shows the cell viability at multiple time points,
which remain above 80%. Size exclusion chromatography with Sepharose® CL-2B (Sigma
CL2B300) was implemented to fractionate vesicles to obtain a better size distribution and
Bicinchoninic Acid assay (BCA) was used to determine protein concentration across the fractions.
Fractions were processed via NanoSight.
Differential Centrifugation
Wild type (WB C6)
cells

were

grown

to

confluency in a T-75 flask
using

pH

7.1

TYI-S-33

medium supplemented with
1% bovine bile and 5% adult
bovine serum. A total of 1 x
107 were harvested via ice
chill, then the cells were
pelleted by centrifugation at
Figure 3.2: Pipeline illustrating vesicle isolation through
differential centrifugation and downstream analysis.

2400xg for 5 minutes at 4°C.
For samples that were treated
with compounds, cells were

put in TYI-S-33 medium without adult bovine serum and each drug was added accordingly. The
concentrations and compounds are as follows: nystatin (27 μM), oseltamivir (20 μM) and myriocin
(27 μM). After 30 minutes, the medium was centrifuged at 2400 x g and the supernatant was
discarded. The cells were washed three times in PBS, centrifuged (2400 x g for 4 min at 4°C) and
placed (~1x107 cells) in 4 ml glass vial containing PBS with 5 mM L-cysteine, 5 mM glucose, and
1mM CaCl2 with a pH of 7.1. The cells were incubated for 3 hours at 37°C to allow for vesicle to
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release. The cell viability was checked by flow cytometry analysis after staining with propidium
iodide. Gradient centrifugation was conducted to isolate the extracellular vehicles (EVs) following
the protocol described by Gavinho et. al. (2020)91 as follows: 600g for 5 minutes, 4000g for 30
minutes, 15,000g for 60 minutes (pellet contains microvesicles) and 100,000g for 240 minutes
(pellet contains exosomes).91
TEM Analysis of Microvesicles
For analysis of vesicles, glutaraldehyde was added to the vesicle preparations at a final
concentration of 1%. Samples were then allowed to absorb onto freshly glow discharged
formvar/carbon-coated copper grids for 10 min. Grids were then washed in dH2O and negative
stained with 1% aqueous uranyl acetate (Ted Pella Inc.) for 1 min. Excess liquid was gently
removed and grids were allowed to air dry. Samples were viewed on a transmission electron
microscope as described above. After three washed in dH2O, samples were en bloc stained in 1%
aqueous uranyl acetate (Electron Microscopy Sciences, Hatfield, PA) for 1 h. Samples were then
rinsed in dH20, dehydrated in a graded series of ethanol, and embedded in Eponate 12 resin (Ted
Pella Inc). Sections of 95 nm were cut with a Leica Ultracut UCT ultra-microtome (Leica
Microsystems Inc., Bannockburn, IL), stained with uranyl acetate and lead citrate, and viewed on
a JEOL 1200 EX transmission electron microscope (JEOL USA Inc., Peabody, MA) equipped
with an AMT 8-megapixel digital camera and AMT Image Capture Engine V602 software
(Advanced Microscopy Techniques, Woburn, MA). ImageJ was used for general vesicle sizing
and counting.92
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NanoSight Methodology
Model LM14C (Malvern) of the NanoSight was used to quantify the number of vesicles
per sample. Samples were diluted by 1/10 in triple filtered PBS. Software NTA 3.2 Dev Build
3.2.16 was used for the analysis. The following are the settings used for the analysis: 30s capture
for a total of three captures, Camera Level: 14, Slider Shutter: 1259, Slider Gain: 366, FPS 25.0.
Protein concentration and Tryptic digestion
Sample protein concentrations were measured by Bicinchoninic acid assay (BCA)
according to manufacturer instructions (Pierce

TM

BCA Protein Assay kit, cat no. 23227). After

protein concentration acquisition was performed in the BioTek Cytation5 plate reader, 100 µg of
each protein sample obtained from the aforementioned step was used for protein digestion by a
modified method (FASP Protein Digestion Expedeon, cat no. 44250), using trypsin (Sigma, cat
no.T6567) to obtain peptides for analyses by mass spectrometry. Next, 200 µl of 12.48 M urea
solution containing 100 mM Tris-HCl pH8 (Urea solution) was mixed with 100 µg of each protein
sample and10 mM of DL-Dithiothreitol (Sigma, Cat no. D0632-5G) was added to each sample to
reduce the disulfide bonds of proteins. Samples were vortexed and placed in a nutating mixer for
45 minutes at room temperature. Samples were then transferred to a 30 kDa filter and centrifuged
for 15 min at 14,000 rpm. An amount of 200 µl of urea solution was added to each spin filter and
centrifuged at 14,000 rpm for 15 min and this step was repeated. Flow through was discarded right
after centrifugation. A 100 mM iodoacetamide solution (10× IOD) was prepared by resuspending
IOD in 100ul of urea solution. A solution of 1× IOD was prepared (1:10 ratio in urea solution) and
100 µl of 1× IOD was added to each spin filter and samples were incubated for 20 min in the dark.
After dark incubation, spin filters were centrifuged at 14,000 rpm for 10 min. Spin filters were
washed twice with 100 µl of urea solution. To remove urea from the samples, 100 µl of 50 mM
ammonium bicarbonate solution was added to spin filter and centrifuged at 14,000 rpm for 15 min.
This step was repeated twice (total of three times). Spin filters were transferred to new spin filter
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tubes and 100 µl of trypsin digestion solution at 1:50 enzyme: protein ratio was added to each
sample and incubated at 37ºC overnight, for 16 hours. Then, 200 µl of 0.1% formic acid LCMS
grade water solution was added to each sample and spin filters were centrifuged at 14,000 rpm for
10 min for elution of peptides. Resulting tryptic peptides were frozen at -80 ºC for two hours and
freeze dried in a lyophilizer. Samples were re-suspended with 100 µl of 0.1% formic acid LCMC
grade water solution for a final concentration of 1µg/µl prior to 1D LC-MS/MS analysis.
Mass Spectrometry Methodology
One microliter of digested peptides (1ug·uL-1) was injected to a custom packed AQUA
5µm, 125Å, C18 (Phenomenex, cat no. 04A-4299) 20cm, 15±1µm, PicoFrit Emitter (New
Objective) equilibrated with optima grade (Thermo Fisher Scientific) 5% solvent B (90%
acetonitrile, 0.1% formic acid) and 95% solvent A (0.1% formic acid). Peptides were loaded and
washed for 10 minutes continuously with 5% solvent B at a flow ratio of 0.500µL·min-1 maintained
throughout the run before beginning the elution gradient. Solvent B was increased to 35% over 85
minutes, then increased to 95% over 5 minutes to maintain a high organic plateau for 9 minutes.
The elution was decreased to 5% solvent B in 1 minute and maintained at 5% solvent B for reequilibration prior to next sample injection for a total runtime of 120 minutes. The mass
spectrometer was equipped with a NanoSprayFlex ion source (ThermoFisher Scientific). Peptides
were analyzed in top 10 data dependent MS2 acquisition by a Q-Exactive Plus Hybrid QuadrupoleOrbitrap mass spectrometer (ThermoFisher Scientific). Full scan parameters were set to 70,000
resolution, 3e6 AGC target, with a scan range of 350 to 1600 m/z. MS2 parameters were set to
17,500 resolution, 1e5 AGC target, isolation window at 3.0 m/z, (N)CE: 30, charge exclusion:
unassigned, 1, >8.
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Bioinformatics
Proteome Discover (PD) 2.5.0.400 (Thermo Fisher) was utilized to ID the proteins from
peptide mixtures. Database for Giardia was downloaded from UniProtKB; http://www.uniprot.org/
on 21 April 2021 with a database 30,894 sequences. A contaminant dataset was run in parallel
compose of trypsin autolysis fragments, keratins, standards found in CRAPome repository and inhouse contaminants. PD analysis parameters are as follows: false-discovery rate (FDR) of 1%,
HCD MS/MS, fully tryptic peptides only, up to 2 missed cleavages, parent-ion mass of 10 ppm
(monoisotopic); fragment mass tolerance of 0.6 Da (in Sequest) and 0.02 Da (in PD 2.1.1.21)
(monoisotopic). Two-high confidence peptides per protein were applied for identifications. PD
dataset was processed through Scaffold Q+ 4.8.2 (Proteome Software, Portland, OR) for protein
quantification. A protein threshold of 99%, peptide threshold of 95%, and a minimum number of
2 peptides were used for protein validation. PCA analysis were carried out using Perseus
(MaxQuant)73 and Venn diagrams we created using FunRich 3.1.4.74–76
Statistical Analysis
Statistical analysis of the data was executed with GraphPad Prism 9.2.0. Values are
represented as means ± standard deviation (SD). NanoSight data had a minimum of three
biological replicates and an ns = 3 per NanoSight run. Proteomic statistics were acquired through
both Scaffold LFQ 4.0.2 and GraphPad Prism. Vesicle samples for proteomic analysis contain an
ns = 3 with technical replicates per sample. The normality of the data was assessed using ShapiroWilk test and statistical analysis were acquired through students T-test. Samples that had a p-value
≤ .05 were considered significant.
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Figure 3.3: The top panels represent positive and negative controls in the flow cytometer. The
lower panels show the progression of cell viability after a 6hr period. Samples were tested after
every hour incubating in a low nutrient vesicle secretion media.
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3.2 RESULTS
Studies suggest that raft microdomains share molecules with secreted vesicles and
participate in exosome biogenesis.93 In the current study, the vesicle profiling was determined via
nano particle tracking (NanoSight) analysis. LR disruptors e.g., nystatin, oseltamivir and
oseltamivir-free acid (OFA, a prodrug of oseltamivir) were employed to examine if they influence
the release of vesicles by Giardia. We also compared the vesicle composition of wild type (cell
lines C6) and VSP overexpressed 67 Giardia cells because VSPs are abundant in rafts (Table 3.3.3).
During giardial vesicle secretion there is a 3hr period where the cells need to incubate in a low
nutrient environment. To assess the viability, flow cytometry was used over a 6-hour period as
shown in figure 3.3 in both C6 and TSA. Overall cells maintain a high viability reducing the
potential to obtain apoptotic bodies. After collection of the EVs and removal of the giardial cells
we ran the samples through a size exclusion column to partition between different sized vesicles
and reduce cellular debris. Figure 3.4 shows the crude vesicle product before purification between
C6 and TSA417 as well as analysis after treatment with either nystatin, oseltamivir or oseltamivir
free acid (OFA), a derivative of oseltamivir. C6 contains a wider distribution of vesicular cargo
compared to TSA417, a giardial strain upregulated in a VSP protein, but overall contain similar
sizes with TSA417 being slightly smaller. When treated with nystatin there is a drastic change that
occurs in TSA417 treated cells, with little to no change in the C6 cells. When treated with
oseltamivir the change becomes apparent between both TSA417 and C6 cells lines, having a
decrease in vesicle size. Finally, OFA has a modest change compared the control vesicles having
only a slight decrease for both C6 and TSA417. The overlap in multiple population of vesicles
however makes the analysis difficult to discern between changes in LV and SV. To better
determine size differences between vesicle population, size exclusion chromatography (SEC) was
implemented on a vesicle population and NanoSight analysis was carried out to test if the column
chromatography could separate the vesicle populations. Figure 3.5 shows multiple fractions
collected after purification using SEC. Overall, we can see the smaller vesicles (exosomes) elute
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in the early fraction 4-7 and the larger vesicle (ectosomes) elute in fraction 8-9. TAS417 and C6
cells were then run through SEC and NanoSight analysis was taken from each fraction. From 114. The biggest issue with this method is the reproducibility. When vesicles samples from TSA417
and C6 were run through SEC there was an overall shift in the vesicle sizing between the two cells
lines as seen in figure 3.6. However, the separation of exosomes and ectosomes becomes less
apparent across the fractions making them harder to characterize individually. In addition to the
SEC methodology, we ran the differential centrifugation to optimize the separation of the two
populations of vesicles.
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Figure 3.4: A comparison of the Nano Sight identifications of vesicles between two cell types
and treatment with three types of compounds with the following concentrations: nystatin (27
µM), oseltamivir (20 µM) and OFA (10 µM)

Figure 3.5: NanoSight analysis of Giardia Vesicles after running size exclusion chromatography.
Samples were obtained from Giardia WB cell line. Vesicles were isolated from Giardia by
collection of the supernatant, concentration of vesicles and size exclusion chromatography.
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Figure 3.6: Shows the vesicle size distribution between C6 and +TSA 417 among different
fractions after size exclusion chromatography.
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Figure 3.7 shows the isolation of the large and small vesicles that was readily reproducible.
Once this technique was optimized, we treated the cells with nystatin (27 μM), oseltamivir (20
μM) and myriocin (27 μM) to giardial cell before vesicle isolation. Figure 3.8 depicts the statistical
analysis of vesicle sizes between the LV and SV of the control and treated cells. Overall, the LV
did not have a statistical change between the treatments. However, the small vesicles display more
drastic changes in reduction of size after treatment with nystatin and oseltamivir; oseltamivir
having a smaller size compared to the nystatin. To check if the LR disruptors could directly change
the vesicle size directly, LVs and SVs were treated with nystatin (27 μM) and oseltamivir (20 μM)
post isolation. Figure 3.9 illustrates the statistics for the NanoSight data obtained from the treated
isolated vesicles. Interestingly, there is no statistical difference between the LVs or the SVs even
after treatment. This provides evidence that the change in vesicle sizes arises in the steps between
the invagination of the vesicular cargo and blebbing of the multivesicular bodies. Further analysis
needs to be conducted to elucidate this potential mechanism. Finally, to qualitatively analyze the
vesicles structures between the control and treatments, TEM analysis was run as seen in figure
3.10. We can see in panel A that the microvesicle blebbing is coming from the plasma membrane
reinforcing the idea that cargo compartmentalized in microvesicle come from the membrane. In
panel B there is a clear reduction in size when cells were treated with nystatin. Even more the
vesicles become reduced after treatment with oseltamivir. Finally in panel C, using ImageJ we ran
the quantification of the total size and number of vesicles from the TEM analysis. We can see that
the mean size of microvesicle secreted from giardia are around 80 nm in size while cells treated
with Nystatin have an average size of around 40nm and cell treated with Oseltamivir have a size
around 15nm. Overall, we can see that the lipid rafts inhibitors are having a pronounced effect on
the vesicle size. This data concurs with the NanoSight vesicle reduction seen in the SV oseltamivir
treated cells from figure 3.8. In addition, there are much more vesicles found in the treated cells.
This may be an effect of the reduction of vesicle size allowing for more vesicle to be displayed per
image.
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To examine the groups of proteins that are differentially changed after treatment we
graphed their volcano plots to show the significance and log2 fold changes as represented in figure
3.11. A threshold fold change of 1.5 was used as a cut off with a p-value ≤ .05. Table 3.3.1 through
3.1.4 represent the proteins that were found to be differentially expressed from the volcano plots
between the control and treatments within the large and small vesicle populations which includes
their protein name, gene name, p-value and log2 fold change. Table 3.1 represents the combined
collective top 10 proteins from the large vesicles and table 3.2 represents the collective abundance
of the top 10 proteins between the small vesicles.
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Figure 3.7: NanoSight characterization from two vesicle populations: Large Vesicles (LVs) and
Small Vesicles (SVs) using nanoparticle tracking analysis (NTA). A comparison of the
identifications of LVs and SVs from Control(C) and after treatment with three types of
compounds with the following concentrations: Nystatin (N) (27 μM), Oseltamivir (O) (20 μM)
and Myriocin (M).

Figure 3.8: NanoSight statistical result comparisons of the vesicle sizes after treatment of
Nystatin (27 μM), Oseltamivir (20 μM) and Myriocin (27 μM) to giardial cell before vesicle
isolation between Large Vesicles (LVs) and Small Vesicles (SVs) from data acquired through
nanoparticle tracking analysis (NTA). T-test was applied between mean ± standard deviation
(SD) of triplicate experiments. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 or ****p ≤ .0001

51

Figure 3.9: NanoSight statistical result comparisons of the vesicle sizes post treatment of
Nystatin (27 μM) and Oseltamivir (20 μM) to vesicle after isolation between Large Vesicles
(LVs) and between Small Vesicles (SVs) from data acquired through nanoparticle tracking
analysis (NTA). T-test was applied between mean ± standard deviation (SD) of triplicate
experiments. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 or ****p ≤ .0001
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Figure 3.10: TEM ultrastructural analysis of A) 95 nm cut giardial cells showing the plasma
membrane and the vesicular budding from the plasma membrane. Panel B) shows giardial
vesicles using negative staining between control and after treatment with Nystatin (27 μM) and
Oseltamivir (20 μM) put arrows to indicate the 20μM) and C) the quantification of the total size
and number of vesicles from the TEM analysis.
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Figure 3.11: Volcano plots showing differentially expressed proteins between Control(C) and
treatments with Nystatin (N) (27 μM) and Oseltamivir (O) (20 μM) within A and B) Large
Vesicles (LVs) and C and D) Small Vesicles (SVs). Volcano plots show –log10 P-values from
the normalized proteomics data exported from Scaffold LFQ versus log2foldchange (FC) across
each contrast (A–F). Thresholds set were p-value ≤ .05 and Log2FC ≤
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-1.5 or ≥ 1.5.

Table 3.1: Top 10 proteins found in Large Vesicles

Protein Name
Tubulin beta chain OS
Gamma giardin
protein OS
Group of Tubulin
alpha chain OS
Putative purine
nucleoside
phosphorylase OS
Arginine deiminase
OS
Alpha-11 giardin OS
Arginine deiminase
OS
Phosphopyruvate
hydratase OS
Pyruvate, phosphate
dikinase OS
14-3-3 protein OS

Accession
Number
V6TBM5

Molecular
Weight
51 kDa

Exclusivity
78%

1_LVC1_1
1119.56

2_LVC2_1
1033.03

3_LVC3_1
918.57

A8W230

36 kDa

100%

469.72

448.78

539.09

33%

419.83

376.93

390.05

V6TQK6
(+1)
Q8ITF3

34 kDa

100%

369.95

303.90

336.14

Q27657

64 kDa

15%

310.03

268.86

310.51

Q4VPP2

35 kDa

83%

299.29

268.56

304.43

V6THM7

64 kDa

3%

276.77

229.99

256.60

Q8WP40

48 kDa

45%

274.35

256.20

250.52

Q27662

98 kDa

31%

268.11

224.39

206.12

E2RU98

29 kDa

100%

261.88

240.29

250.52
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Table 3.2: Top 10 proteins found in Small Vesicles

Protein Name
VSP with INR OS
Peptidyl-prolyl cistrans isomerase OS
Peptidyl-prolyl cistrans isomerase OS
Beta-giardin
(Fragment) OS
VSP with INR OS
VSP with INR OS
Eukaryotic
translation initiation
factor 5A OS
Putative_PNPOx
domain-containing
protein OS
Translation
initiation inhibitor
OS
Carbamate kinase
OS

Accession
Number
A0A644F364

Molecular
Weight
73 kDa

E1EW75

18 kDa

13%

V6TZ19

20 kDa

5%

A0A0F6PP63

26 kDa

42%

A8BAX4
A8BZ11

75 kDa
76 kDa

6%
83%

A8BZ89

17 kDa

100%

V6TH20

A8BH09
A8BB85

15 kDa

Exclusivity

1_SVC1_1

2_SVC2_1

3_SVC3_1

45%

1312.73

1002.75

963.24

1282.77

1258.88

1388.05

857.90

906.65

1034.23

626.90
561.04
555.59

457.46
396.14
632.70

485.53
357.67
557.94

424.87

352.22

353.82

375.84

371.79

333.40

310.48

352.22

367.42

294.14

313.09

340.21

21%

13 kDa

100%

34 kDa

41%
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Table 3.3.1: Significant proteins from volcano plot Lipid Rafts Control v Nystatin
LV_C_V_N
Protein names
60S acidic ribosomal protein P0
60S ribosomal protein L7a
Alcohol dehydrogenase 2 (EC 1.1.1.1)
Alcohol dehydrogenase 3 (Alcohol dehydrogenase lateral transfer
candidate)
Alpha-14 giardin
Beta giardin (Fragment)
Coiled-coil protein
DEAD box RNA helicase Vasa
DEAD-box helicase family protein
H(+)-transporting two-sector ATPase (EC 7.1.2.2)
Kinase, NEK
Kinase, NEK (Kinase, NEK-frag)
LSU ribosomal protein L10AE
Malate dehydrogenase (EC 1.1.1.37)
Phosphoglycerate kinase (EC 2.7.2.3)
Pyruvate kinase (EC 2.7.1.40)
Pyruvate kinase (EC 2.7.1.40)
Pyruvate kinase (EC 2.7.1.40)
Pyruvate:ferredoxin oxidoreductase
Pyruvate-flavodoxin oxidoreductase
Pyruvate-flavodoxin oxidoreductase
Ribokinase (EC 2.7.1.15) (Fragment)
Ribokinase (RK) (EC 2.7.1.15)
Ribosomal protein P1B
Ribosomal protein S28
Serine/threonine protein kinase
Serine/threonine protein kinase
Serine/threonine-protein phosphatase (EC 3.1.3.16)
SSU ribosomal protein S17P
T-complex protein 1 subunit gamma
Translation initiation factor eIF-4A, putative
Uncharacterized protein
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Gene
V6TAM8
A8BLL7
Q9NBW5

pvalue
0.036
0.035
0.031

log2fc
-2.04
-0.70
-1.14

E2RTP3

0.038

-1.52

A0A644F164
A0A3G9JZW8
A8B3P4
A0A644F7Y6
V6TA91
V6TJE6
A8BH18
A8BH24
V6TJ23
Q9Y1U1
A8BGV6
A8BW44
E1F1S1
V6U352
Q24982
C6LQL8
E1EYJ1
V6TIZ4
A8B6Y7
A8BKF1
E1F1V5
V6TH47
V6TFX1
V6TG04
V6TF82
A8B8R9
E1EXB1
A8BH09

0.041
0.0081
0.028
0.016
0.016
0.02
0.038
0.014
0.046
0.043
0.025
0.026
0.018
0.018
0.017
0.019
0.0084
0.011
0.029
0.002
0.026
0.00023
0.036
0.00023
0.0062
0.0026
0.043
0.025

-1.66
0.87
0.79
-2.03
-2.03
-1.17
-0.81
-0.66
-1.81
-2.25
-1.64
-1.98
-1.65
-1.65
-1.04
-1.20
-0.65
-2.55
-2.03
-2.39
1.03
-2.21
-0.94
-2.21
-2.22
-2.78
-1.64
3.07

V6TCW1
A8BPV3

Uncharacterized protein
Vacuolar ATP synthase subunit B (EC 3.6.3.14)

0.0055
0.024

0.82
-2.13

Table 3.3.2 Significant proteins from volcano plot Large Vesicle Control v Oseltamivir
LV_C_V_O
Protein names
AAA family ATPase
Actin related protein
Adenine phosphoribosyltransferase
Alcohol dehydrogenase 2 (EC 1.1.1.1)
Ankyrin repeat protein
Ankyrin repeat protein 1
Ankyrin repeat protein 1 (Protein 21.1)
CCT-epsilon (T-complex protein 1 subunit epsilon)
CCT-epsilon (T-complex protein 1 subunit epsilon)
CCT-epsilon (T-complex protein 1 subunit epsilon)
CCT-theta
Eukaryotic translation initiation factor 5A (eIF-5A)
Glutamate synthase
Hybrid cluster protein (Hybrid cluster protein lateral transfer
candidate)
Isoleucyl-tRNA synthetase (EC 6.1.1.5)
Peroxiredoxin 1 (EC 1.11.1.-)
Phosphatidylinositol-4-phosphate 5-kinase, putative
Protein 21.1
Protein 21.1
Protein 21.1
Protein disulfide isomerase (Fragment)
Putative_PNPOx domain-containing protein
Pyruvate kinase (EC 2.7.1.40)
Pyruvate kinase (EC 2.7.1.40)
Ribose 5-phosphate isomerase (EC 5.3.1.6)
Serine/threonine protein kinase
Serine/threonine protein kinase
Thioredoxin domain-containing protein
Thioredoxin-like protein
Translation initiation factor eIF-4A, putative
Uncharacterized protein
Uncharacterized protein
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Gene
A8BUY7
A8BUF3
Q967M2
Q9NBW5
V6TC33
A8B861
A8B821
V6TWB6
E1EVQ1
Q9GU01
E1EXS9
A8BZ89
A8BRQ2

pvalue
0.022
0.047
0.025
0.029
0.036
0.039
0.012
0.043
0.024
0.035
0.043
0.044
0.041

log2fc
0.66
0.94
1.43
-0.79
2.86
3.28
2.24
1.48
1.60
1.95
1.14
-0.61
2.16

A8BLL4

0.046

1.10

Q5KTW2
A8BYC4
E1F573
E1F4P2
E1F6F5
E1F9S5
V6TK17
V6TH20
E1F1S1
V6U352
A8B2K2
V6TVT1
V6U2E9
C6LS73
V6T9Y0
C6LYS4
V6U3H0
E1F432

0.012
0.046
0.054
0.0064
0.012
0.023
0.043
0.032
0.045
0.045
0.0006
0.022
0.0068
0.051
0.051
0.038
0.036
0.05

1.80
-0.68
1.62
-0.64
0.87
1.57
-0.80
-0.67
-0.88
-0.88
2.13
1.74
1.78
-1.19
-1.19
0.86
1.79
1.88

E1EX25
A8BJK2
V6TBQ2
A8BTV4
E1F2P1

Uncharacterized protein
Uncharacterized protein
Variant-specific surface protein (Fragment)
VSP
Wos2 protein

0.018
0.0075
0.00023
0.0041
0.021

1.93
3.33
-2.21
-1.67
0.66

Table 3.3.3: Significant proteins from volcano plot Large Vesicle Control v Nystatin

SV_C_V_N
Protein names
Adenine phosphoribosyltransferase
Alpha-11 giardin
Arginine deiminase
Arginine deiminase (EC 3.5.3.6)
A-type flavoprotein lateral transfer candidate
A-type flavoprotein lateral transfer candidate (Flavoprotein)
Beta giardin (Fragment)
Carbamate kinase
Carbamate kinase
Chromosome segregation protein SMC
Coiled-coil protein
Coiled-coil protein
Coiled-coil protein
Cyst wall protein 1
Cystatin
Deflagellation inducible protein (Sjogren's syndrome nuclear
autoantigen 1-like protein)
Delta giardin
Elongation factor 1-alpha (EF-1-alpha) (14 nm filament-associated
protein) (Fragment)
Elongation factor 1-alpha (Fragment)
Eukaryotic translation initiation factor 5A (eIF-5A)
FixW protein, putative (Putative FixW protein)
Fructose-bisphosphate aldolase
Gamma giardin protein (Giardin gamma chain)
Giardia trophozoite antigen GTA-1
Glyceraldehyde-3-phosphate dehydrogenase (EC 1.2.1.12)
Glyceraldehyde-3-phosphate dehydrogenase 1 (GAPDH) (EC
1.2.1.12)
GTP-binding nuclear protein
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Gene
Q967M2
Q4VPP2
V6THM7
Q27657
C6LS90
V6TS50
A0A3G9KB83
A8BB85
V6TVY8
V6TS02
E1F0K8
A8B3P4
C6LYM5
C6LNU6
A8BPS7

pvalue
0.00015
0.0076
0.0001
0.0001
0.0049
0.0016
0.048
0.00035
0.0001
0.00047
0.048
0.012
0.035
0.00045
0.049

log2fc
-3.94
-7.01
-6.25
-6.25
-2.23
-2.93
-1.23
-2.10
-1.91
-3.83
-4.40
-2.06
3.04
-5.60
1.20

A8BS67

0.0041

0.83

E1F6V5

0.03

-4.27

Q08046

0.018

-2.27

E9M2H0
A8BZ89
A8BDV4
V6TLE8
A8W230
E2RU76
V6TSB8

0.018
0.00016
0.0088
0.03
0.012
0.0072
0.0001

-2.27
0.91
2.35
-5.23
-6.86
-6.76
-4.80

P53429

0.00022

-5.33

E1F4L8

0.0079

-4.30

Heat shock factor binding protein
Heat shock protein 70 (Fragment)
High cysteine membrane protein Group 1
High cysteine membrane protein Group 1
Uncharacterized protein
LSU ribosomal protein L11P (Fragment)
Nucleoside diphosphate kinase (EC 2.7.4.6)
Ornithine carbamoyltransferase
Ornithine carbamoyltransferase
Ornithine carbamoyltransferase
Peptidyl-prolyl cis-trans isomerase (PPIase) (EC 5.2.1.8)
Peptidylprolyl isomerase (EC 5.2.1.8)
Phosphoglycerate kinase (EC 2.7.2.3)
Protein disulfide isomerase (Fragment)
Protein Translation Elongation Factor 1A (EF-1A) (Fragment)
Putative purine nucleoside phosphorylase (UPL-1)
Putative_PNPOx domain-containing protein
Putative_PNPOx domain-containing protein
RAN binding protein 1
Rhodanese-like protein
Ribosomal L38e
Ribosomal protein L23A
Ribosomal protein L31B (Ribosomal protein L31e)
Ribosomal protein P2
Ribosomal protein S28
Thioredoxin
Thioredoxin
Thioredoxin-like protein
Tubulin alpha chain
Tubulin-specific chaperone A
Ubiquitin
Ubiquitin
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
UVR domain-containing protein
UVR domain-containing protein
Variant-specific surface protein 1267
Variant-specific surface protein AS4 (Variant-specific surface
protein S1)
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A8B924
V6TK06
A8BCN1
A8BFJ7
A8BI78
V6T9U4
A8BMG9
O76458
E1EZW7
C6LPK2
E1EW75
E1F402
A8BGV6
V6TK17
V6TFY1
Q8ITF3
V6TH20
E1F596
A8B911
A0A644F3A6
A8B481
A8BMP6
A8BMP3
A8BCP0
E1F1V5
A8B5E9
A8B4C4
V6T9Y0
V6TQK6
V6TAQ7
A8BJ08
C6LQV8
A8BKV3
E1EZS4
V6TJE5
A8BWL4
V6TCF8
C6LRE4
V6TEP4
Q07317

0.0079
0.003
0.047
0.047
0.0041
0.0082
0.0044
0.0001
0.0001
0.0001
0.052
0.0064
0.0028
0.0014
0.039
0.016
0.0044
0.00021
0.025
0.012
0.018
0.04
0.011
0.0001
0.002
0.0046
0.0046
0.027
0.0015
0.0037
0.0055
0.0055
0.0001
0.00015
0.0081
0.0076
0.043
0.015
0.015
0.0057

-4.30
-2.91
-3.65
-3.65
-3.04
-5.82
-2.00
-2.74
-2.02
-2.00
0.63
2.58
-5.43
1.84
-6.45
0.72
1.16
1.20
0.95
0.94
1.62
-5.81
-1.87
-7.64
1.55
1.15
1.15
3.17
-5.10
1.36
0.92
0.92
-8.22
-3.94
1.79
4.94
5.58
-4.09
-4.09
-2.49

Q8I0P4

0.0029

-6.21

Q9GS24
A8BQM2
A0A644F288
A8BJT8
E2RTN8
A8BWQ1
E2RTV3

Variant-specific surface protein VSP9B10
VSP
VSP
VSP
VSP AS8
VSP with INR
VSP with INR

0.0074
0.014
0.0076
0.0076
0.00015
0.011
0.013

-0.95
-4.95
-4.50
-4.50
-4.89
-2.26
-2.24

Table 3.3.4: Significant proteins from volcano plot Small Vesicle Control v Oseltamivir

SV_C_V_O
Protein names
14-3-3 protein
40S ribosomal protein S21
40S ribosomal protein S21
40S ribosomal protein S30
Acetyl-CoA synthetase
Acetyl-CoA synthetase
Actin related protein
Actin related protein
Actin related protein
Alpha-11 giardin
Alpha-7.3 giardin
Aminoacyl-histidine dipeptidase
Aminoacyl-histidine dipeptidase
Ankyrin repeat protein 1 (Protein 21.1)
Ankyrin repeat protein 1 (Protein 21.1)
Ankyrin repeat protein 1 (Protein 21.1)
ARF GAP
Arginine deiminase
Arginine deiminase
Arginine deiminase
Arginine deiminase (EC 3.5.3.6)
ATP synthase subunit E family protein
ATPase involved in DNA repair/chromosome segregation
A-type flavoprotein lateral transfer candidate
A-type flavoprotein lateral transfer candidate (Flavoprotein)
Beta giardin (Fragment)
Beta-giardin (Fragment)
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Gene
E2RU98
C6LWT7
A8B484
A0A644F843
E2RU11
E1F0V6
C6LWG6
E1F6P9
A8BUF3
Q4VPP2
E1F838
V6TNZ1
V6T7L3
A8B820
A8B6R1
A8B440
E1F0N6
V6THM7
E1F0W3
C6LS39
Q27657
A8BBC1
V6T9C3
C6LS90
V6TS50
A0A3G9K727
A0A1B1SP02

pvalue
0.0076
0.024
0.0039
0.0067
0.049
0.049
0.037
0.031
0.011
0.02
0.01
0.04
0.014
0.0001
0.0001
0.00019
0.013
0.011
0.052
0.045
0.018
0.025
0.0001
0.0061
0.0036
0.026
0.052

log2fc
4.98
1.64
1.96
2.51
5.10
5.10
3.59
3.94
4.45
0.92
1.53
3.70
5.20
3.69
3.81
5.63
5.31
0.72
1.10
1.19
0.81
4.02
5.67
-1.70
-1.66
-0.70
-1.17

Beta-giardin (Fragment)
Beta-giardin (Fragment)
Beta-giardin (Fragment)
Beta-giardin (Fragment)
Uncharacterized protein
Carbamate kinase
Carbamate kinase
Chromosome segregation protein SMC
Chromosome segregation protein SMC
Chromosome segregation protein SMC
Coiled-coil protein
Coiled-coil protein
Coiled-coil protein
Coiled-coil protein
Cyst wall protein 1
Cytidine deaminase (EC 3.5.4.5) (Cytidine aminohydrolase)
Cytosolic HSP70 (Cytosolic heat shock protein 70)
Delta giardin
Delta giardin
DUF1681 domain-containing protein
Elongation factor 1 beta, guanine nucleotide exchange domain
protein
Elongation factor 1-alpha (EF-1-alpha) (14 nm filament-associated
protein) (Fragment)
Elongation factor 1-alpha (Fragment)
Eukaryotic translation initiation factor 5A (eIF-5A)
FixW protein, putative (Putative FixW protein)
Fructose-bisphosphate aldolase
Gamma giardin protein (Giardin gamma chain)
GLORF-C4 (Fragment)
Glucosamine-6-phosphate isomerase (EC 3.5.99.6) (Glucosamine6-phosphate deaminase)
Glyceraldehyde-3-phosphate dehydrogenase (EC 1.2.1.12)
Glyceraldehyde-3-phosphate dehydrogenase 1 (GAPDH) (EC
1.2.1.12)
GTP-binding nuclear protein
Heat shock protein 70 (Fragment)
Histone H2B
H-SHIPPO 1 (SHIPPO repeat domain-containing protein)
H-SHIPPO 1 (SHIPPO repeat domain-containing protein)
Hybrid cluster protein (Hybrid cluster protein lateral transfer
candidate)
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A0A3G1Z1L9
Q0ZAK4
I6Z0X4
A0A5S9HWF0
A0A3G4S8P8
A8BB85
V6TVY8
V6TSF6
V6TS02
V6TYX9
A8B3P4
A8BAF5
E1F0K8
A8BC51
C6LNU6
A8B7B3
A8BCR6
E1F6V5
A8BEZ6
V6TLU7

0.036
0.013
0.0049
0.052
0.045
0.00045
0.00011
0.031
0.00016
0.0001
0.0027
0.02
0.00019
0.0007
0.0059
0.0034
0.00055
0.0049
0.0028
0.0047

-0.96
-0.87
-0.81
-0.74
-0.72
0.67
0.72
0.70
2.64
6.99
1.06
2.43
2.62
4.51
-2.74
4.03
4.16
1.60
1.93
5.55

V6TRV2

0.022

2.90

Q08046

0.00097

1.95

E9M2H0
A8BZ89
A8BDV4
V6TLE8
A8W230
A0A141FNT7

0.014
0.012
0.0086
0.0001
0.0012
0.021

0.94
-0.65
1.55
3.60
1.58
3.58

V6TJX3

0.0049

5.32

V6TSB8

0.036

-0.70

P53429

0.041

-0.66

E1F4L8
V6TK06
A8BI78
A8B9X5
A8B9W3

0.00012
0.0001
0.017
0.026
0.026

3.15
2.14
-1.14
2.04
5.47

A8BLL4

0.00055

2.01

Malate dehydrogenase (EC 1.1.1.37)
Median body protein
Mitotic spindle checkpoint protein MAD2
Mucin-like protein
NAD(P)H oxidoreductase
NADPH oxidoreductase, putative
NADPH oxidoreductase, putative (Putative NADPH
oxidoreductase)
Nucleoside diphosphate kinase (EC 2.7.4.6)
ORF-C4 (Fragment)
Ornithine carbamoyltransferase
Ornithine carbamoyltransferase
Ornithine carbamoyltransferase
Peptidyl-prolyl cis-trans isomerase (PPIase) (EC 5.2.1.8)
Peptidyl-prolyl cis-trans isomerase (PPIase) (EC 5.2.1.8)
Peptidylprolyl isomerase (EC 5.2.1.8)
Phosphatidylinositol transfer protein alpha isoform
Phosphatidylinositol-4-phosphate 5-kinase, putative
Phospholipid-binding Copine Family Protein
Prefoldin subunit family protein
Protein 21.1
Protein 21.1
Protein 21.1
Protein disulfide isomerase
Protein disulfide isomerase (Fragment)
Protein disulfide isomerase (Protein disulfide isomerase PDI1)
Protein disulfide isomerase PDI4
Protein Translation Elongation Factor 1A (EF-1A) (Fragment)
Putative 26S proteasome regulatory subunit
Putative plectin/S10 domain protein
Ribonucloprotein
Ribose 5-phosphate isomerase (EC 5.3.1.6)
Ribosomal L38e
Ribosomal protein P2
SAS-6_N domain-containing protein (Fragment)
Ser/Thr protein kinase
Ser/Thr protein kinase
Spindle pole protein, putative
Spindle pole protein, putative
SSU ribosomal protein S12E
START domain-containing protein
Stress-induced-phosphoprotein 1
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Q9Y1U1
A8BER9
A8BQB1
A0A644F280
Q95VX9
E1EXL9

0.034
0.0001
0.029
0.0097
0.0021
0.0073

5.23
8.02
4.11
-2.15
3.91
3.57

A8BSH8

0.0019

5.70

A8BMG9
Q9BI02
C6LPK2
E1EZW7
O76458
V6TZ19
E1EW75
E1F402
A8BQI1
E1F573
V6TP72
V6TJ49
C6LWW4
E1F1N5
A8B5Q6
V6TF84
V6TSL5
E2RTR8
A8B3I4
V6TFY1
A0A644EZH6
V6TK71
V6TC42
A8B2K2
A8B481
A8BCP0
V6TLT7
C6LN82
A8BH21
A8BML6
A8B7S6
V6TAA9
A8BE80
E1F0R6

0.0062
0.021
0.0001
0.00011
0.001
0.0011
0.00022
0.021
0.012
0.0013
0.0001
0.0025
0.0001
0.0001
0.0011
0.0044
0.02
0.0001
0.0044
0.014
0.0074
0.025
0.0001
0.0012
0.01
0.0001
0.012
0.0001
0.0033
0.051
0.003
0.053
0.041
0.00034

-1.60
3.58
-1.36
-1.15
-1.14
-1.01
-0.93
1.16
4.19
5.73
5.16
4.02
5.35
5.57
7.57
3.42
2.43
4.02
3.42
1.34
-2.26
5.41
5.79
4.01
2.13
-5.23
4.19
2.09
3.69
0.83
4.77
4.51
4.22
2.22

Stress-induced-phosphoprotein 1
Thioredoxin
Thioredoxin domain-containing protein
Thioredoxin peroxidase (Fragment)
Thioredoxin peroxidase (Fragment)
Thioredoxin-like protein
Translation initiation inhibitor
Trichohyalin
Tubulin alpha chain
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
Uncharacterized protein
UVR domain-containing protein
UVR domain-containing protein
Variant-specific surface protein
Variant-specific surface protein (Fragment)
Variant-specific surface protein 1267
Variant-specific surface protein AS4 (Variant-specific surface
protein S1)
Variant-specific surface protein VSP9B10
Variant-specific surface protein WB/9B10-B
Viral A-type inclusion protein repeat protein
VSP
VSP
VSP
VSP
VSP
VSP
VSP
VSP
VSP
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A8BX22
A8B5E9
C6LS73
V6U3Q0
V6TBY0
V6T9Y0
A8BH09
A8BU68
V6TQK6
E1EZS4
A0A644EYN4
A8BKV3
V6T9K9
V6TP98
A8BS87
V6TJE5
A0A644F787
A8BAZ8
A8B8M0
A8B470
A8BKI2
V6TCF8
A8B5U0
C6LRE4
V6TEP4
V6TEK2
V6TIS4
Q07317

0.00014
0.018
0.026
0.0032
0.0001
0.017
0.0024
0.017
0.0015
0.0074
0.0043
0.00023
0.00016
0.002
0.0019
0.0069
0.035
0.0025
0.0044
0.015
0.00043
0.0001
0.00085
0.00021
0.0002
0.007
0.017
0.011

2.42
-0.67
2.07
1.40
4.97
2.40
-0.87
3.28
-5.10
-2.26
-1.23
-1.21
-1.07
-1.02
1.16
1.28
1.43
4.02
4.35
4.50
5.55
5.67
6.57
2.27
2.70
-2.24
-3.43
-1.53

Q8I0P4

0.0089

-2.18

Q9GS24
Q95WU1
V6U2F5
A8B497
A0A644F647
A0A644F158
A8BJT8
A0A644F288
A8BTV4
A8BP21
A8BPL3
A0A644EY08

0.0012
0.00047
0.02
0.0002
0.049
0.0025
0.018
0.018
0.012
0.019
0.022
0.032

-2.76
-2.37
2.43
-2.88
-2.77
-2.34
-2.09
-2.09
-1.84
-1.37
-1.32
-1.22

A8BVA8
A8B1N7
E2RTN8
A8BC41
A8BAX4
A8BWQ1
A8BB06
A0A644F364
A8BZ11
E2RTV3

VSP (VSP with INR)
VSP (VSP with INR)
VSP AS8
VSP with INR
VSP with INR
VSP with INR
VSP with INR
VSP with INR
VSP with INR
VSP with INR
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0.00048
0.039
0.00015
0.007
0.0092
0.0078
0.00048
0.0033
0.00036
0.023

-1.65
-1.61
-4.89
-2.24
-1.84
-1.82
-1.77
-1.77
-1.66
-1.39

Chapter 4: In vivo treatment of Giardiasis
4.1 INFECTION AND TREATMENT
Anti-giardial activities of oseltamivir were evaluated in laboratory mice. Animal studies
were performed with IACUC approval at the University of Texas at El Paso. Briefly, 3-4 weeks
old mice (C57B6) were given a cocktail of three antibiotics, i.e., ampicillin, neomycin (G418), and
vancomycin to remove bacterial flora in the gut. This was helpful to establish Giardia infection.94
All antibiotics were given at a concentration of 1mg/mL in their drinking water for 72 h to allow
a clearance of their microbiota. Mice were then infected with 1 x 107 luciferase expressing (PNT5Luc+) trophozoites, resuspended in 100 μl of phosphate-buffered saline (PBS) for 48 h before
initiating the treatment. For the treatment, we used metronidazole as a positive control and
oseltamivir. The doses of oseltamivir were 1.5mg/kg and 3 mg/kg per mouse, respectively.
Treatment was gavaged every day in 100μl PBS. Mice were imaged through the IVIS to track
infection and fecal material was collected for cysts counting.
4.2 RESULTS
Efficacy of Oseltamivir in Vivo Mice Models
We see that the metronidazole (positive control) inhibits the progression of the infection as
expected. When comparing the infection rate between oseltamivir and metronidazole, we see there
is a decrease of infection. In the Figures 4.1 and 4.2 are IVIS imaging showing oseltamivir and its
derivatives are effective in decreasing the overall infection. In Figure 4.3, we see a decrease in
infection as measured by low cyst release by mice. An increase in concentration of oseltamivir
also lead to an overall decrease in cyst numbers. The most effective treatment that seemed to lower
both the cysts count and infection was oseltamivir followed by the oseltamivir derivative SP1568.
Current in vitro tests with OFA analogues show promise in their efficiency. Further tests in mice
will be conducted to find the optimal efficacy of OFA analogue.
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Figure 4.1: Graph shows Giardia infection in various groups after treatment with lipid raft
disruptors. Luciferase substrate was injected into mice and luciferase expression was quantified
with the IVIS system.
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Figure 4.2: Graph shows Giardia infection in various groups after treatment with lipid raft
disruptors. Luciferase substrate was injected into mice and luciferase expression was quantified
with the IVIS system.

Figure 4.3: Giardia cyst counts in feces of mice belonging to 4 distinct groups: Control,
metronidazole 3mg/kg and oseltamivir at 1.5 mg/kg and 3mg/kg. Fecal counts were normalized
by dividing the total amount of cysts identified to the total fecal weight collected. A total of 5 mice
were used between each group.
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Chapter 5: Discussion

5.1 PROTEOMIC COMPARISONS OF LR AND EVS

Bioinformatic Enrichment of Proteomic Outputs
DAVID (database for annotation, visualization, and integrated discovery) was used in the
enrichment

of

the

biological

fractions

before

and

after

treatment

(https://david.ncifcrf.gov/home.jsp, version 2021, accessed on March 1, 2022). The database
enrichment includes Gene ontology (GO, http://geneontology.org/, accessed March 1, 2022) and
divides gene function descriptions into three categories: biological process (BP), cellular
component (CC), and molecular function (MF). Statistical significance was assigned to terms with
a p value of less than 0.05. Giardia’s proteomic identifications between LRs and EVs were
searched against a large comprehensive repository of vesicle data known as Vesiclepedia.95,96
Proteomic Comparisons between Lipid Rafts and Extracellular Vesicles
Having obtained a comprehensive overview of the LR proteomic composition we wanted
to see proteins that may be related between the LRs, LVs and SVs. Figure 5.1 shows a Venn
diagram representing the similarity between LRs and EVs. Overall, there is large overlap between
the two showing the potential interplay between the two. Additionally in supplement 4 the list of
identified proteins found between these groups are displayed. Many of the common virulence
factors as described before are present between the groups.
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Figure 5.1: Venn diagram showing the protein overlaps between LR, LV and SV

To identify the proteins that that were differentially expressed we plotted volcano plots
between the treated cells with nystatin and oseltamivir and saw if there were any drastic changes
between LR, LV and SVs. The most notable change can be seen between the SV with proteins
having an expression almost 5 times up or down regulated compared to the control. Tables 2.1.1,
2.1.2 and table 3.3.1 through 3.1.4 show all the significant proteins between each group showing
the protein name, accession name and p-value computed from scaffold and log2fc compared to the
control.
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Figure 5.2: Volcano plots showing differentially expressed proteins between Control (C) and
treatments with Nystatin (N) (27 μM) and Oseltamivir (O) (20 μM) within A and B) Giardial Lipid
Rafts(LRs), C and D) Large Vesicles(LVs) and E and F) Small Vesicles(SVs). Volcano plots show
–log10 P-values from the normalized proteomics data exported from Scaffold LFQ versus
log2foldchange (FC) across each contrast (A–F). Thresholds set were p-value ≤ .05 and Log2FC
≤ -1.5 or ≥ 1.5.
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To get a better illustration on the proteomic composition between groups we ran
enrichments using the Bioinformatics tool DAVID seen in Figure 5.3. This allowed us to obtain
the biological, molecular and compositional characteristics between the cellular components
before and after treatment. The LR and LV overall contain similar protein composition between
the control and the treatments. The more drastic alteration to protein characteristics occurs after
treatment with LR disruptors in the SV fractions. We can see that there are changes in the class of:
cytoskeletal organization, cytoskeletal and cytosolic ribosomal components, and structural
molecular activity.
To sub classify the large array of protein data that was identified between LRs, LVs and
SVs and their modulation in comparison to their controls we extracted the most common virulent
factors that are mentioned in the literature. Figure 5.4 illustrates groups of virulence proteins: such
as arginine deiminase, carbamate kinase, elongation factor, giardins, high cysteine membrane
proteins (HCMPs), ornithine carbamoyltransferase (OCT), tenascin, and variant surface proteins
(VSPs). LRs, LVs and SVs were given each a respective heat map to see differences between each
group. Protein samples included have a p-value ≤ .05 between normalized data in scaffold and
have been transformed to a Z-score for visual simplification. The heatmap representation shows
that specific groups of virulence proteins are found in higher abundances in certain fractions. It
can be seen that HCMPs and tenascin are found more prevalent in the LR fractions. However, we
see that the virulence factors are highly prevalent in the vesicle fractions such as arginine
deaminase, carbamate kinase, giardin, OCT, and VSPs. The analysis also demonstrates that the
more dramatic changes in abundance of virulence factors occur after treatment with LR disruptors
in the SV fraction. There are drastic decreases in at least seven of the eight virulence factors in the
SV after giardial cells were treated with LR disruptors. Figure 5.5 represents the general
mechanism for how these virulence factors are pathogenic. An example of this is the degradation
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of arginine which is found in the intestinal milieu. Proteins found localized both in the giardial
lipid rafts and microvesicles in combination potentiate this effect. Similarly in Figure 5.6 we
created a giardial model representing the interplay between lipid rafts, microvesicles and host
intestinal cells. This summarization of the figure integrates the lipid rafts components and their
importance for both attachment and microvesicle secretion.

Figure 5.3: Protein Enrichment using DAVID was executed on RAW data across all groups
including Lipid Raft: Control (LR_C), Nystatin (LR_N), Oseltamivir (LR_O), Large Vesicle:
Control (LV_C), Nystatin (LV_N), Oseltamivir (LV_O) and Small Vesicle: Control (SV_C),
Nystatin (SV_N), Oseltamivir (SV_O) as seen in panel A. This was to determine their B)
Biological Process C) Cellular Component and D) Molecular Functions. Charts are normalized to
a 100% for a more indicative representation of changes in process, component or function across
fractions and treatment.
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Figure 5.4: Differentially expressed heat map patterns of known giardial virulence factors such as
arginine deiminase, carbamate kinase, elongation factor, giardins, high cysteine membrane
proteins(HCMPs), ornithine carbamoyltransferase (OCT), tenascin, and variant surface proteins
(VSPs). Each heat map contains proteins between control (C) and treatments with nystatin (N) (27
μM) and oseltamivir (O) (20 μM) within isolated LRs, LVs and SVs. Protein samples included
have a p-value ≤ .05 between normalized data in scaffold and have been transformed to a Z-score
for visual simplification.
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Figure 5.5: Giardial virulence model of free-floating arginine is taken up from the intestinal milieu
through the Arginine-Ornithine Antiporter (ArcD) that can go through the dihydrolase pathway.
Arginine deiminase (ADI) converts the arginine into citrulline and ammonia (NH3).11,43,97,98
Citrulline is then converted into ornithine and carbamoyl phosphate (CP) by ornithine carbamoyl
transferase (OCT). Finally, carbamate kinase (CK) converts CP into NH3, carbon dioxide, and
ATP. One of the virulence factors that is released is ornithine via the arginine-ornithine
antiporter.11,43,97,98 Ornithine blocks the cationic amino acid transporters (CAT) of IECs preventing
the uptake of arginine.11,43,97,98 In addition, arginine is degraded extracellularly by ADI and OCT
present on vesicles released from Giardia upon interaction. All this leads to reduced arginine
availability within the host IEC as an increase in ornithine. As shown within this study, the
consequences are reduced polyamine levels in IECs that result in cell cycle arrest via upregulation
of cell cycle block genes (GADD45A, BTG3)
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Figure 5.6: Giardial model representing the interplay between lipid rafts, microvesicles and host
intestinal cells. The left panel shows the blebbing of microvesicles from lipid raft membrane
domains as well as exosome blebbing. In the bottom left panel, giardial cell with intact lipid rafts
can attach to the membrane. In addition to this, microvesicles are secreted to modulate host
response and allow the break down the intestinal cell integrity. The right side of the panel shows
giardial cells treated with either oseltamivir or nystatin. Disrupted lipid rafts affected architecture
and composition of exosomes as well as producing changes of protein content from microvesicles.
Lipid raft disruptors reduced the overall number of virulence factors found in microvesicles as
well as changing their size. In addition to this, lipid raft disruption affects the overall ability for
trophozoites to attach to intestinal cells.
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5.2 FINAL DISCUSSION
The interdependence of LRs and EVs is now established.
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There is a growing body of

literature describing the biochemical stability and viability of these raft membranes.100–102 Giardia
is not an intracellular parasite, so the methods of host modulation were not well understood until
recently. There have been advancements however in the study of giardia secretome and exosomal
secretion. Current proposed models suggest that there is a combination of proteases, ornithine
carbamoyl transferases (OCT) and arginine deaminases (ADI) found in EVs that assist with the
degradation of tight junctions and modulate host response.103 The first in depth analysis of the
giardial secretome originates with the Svärd group elucidating both parasite and host proteins that
are released in axenic culture.104 A multitude of known giardial pathogenic markers were described
to be identified including Arginine metabolizing enzymes (AMEs) such as ADI and OCT, giardins,
VSPs, HCMPs, cathepsins, tenascins and a wide array of potentially pathogenic proteins such as
enolases and glycolytic enzymes.104

VSPs are one of the abundant proteins found on both the membrane and vesicles. Giardia
is known to circumvent the immune response by triggering antigenic variation through changes in
chromatin state along with RNA interference.105–107 In other parasites such as Trypanasoma brucei,
variant surface glycoproteins (VSGs) are known to have effect on immunity by reducing B-cell
populations and preventing a long lasting immune response.108 This could be a potential modulator
of giardial VSPs. New VSP transcripts are also known to be induced when there is a secretion of
a specific VSP called TSA 417 (trophozoite’s surface antigen 417).109 We can see that one of the
most abundant proteins on the vesicles is TSA 417, which could suggest that the giardial cells are
undergoing constant antigenic switching. When analyzing vesicle secretions via Dynamic Light
Scattering (DLS), the TSA overexpressed giardial cells have drastic changes in the vesicle
profiling as shown in Figure 3.4. As discussed, modulating vesicle formation could impact giardial
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modulation of host intestinal cells. In regards to arginine metabolism, it has been shown that it
Giardia inhibits cytokine production, reduces nitric oxide production, and inhibits cell
proliferation.44,45,110
Identified proteins in LVs, SVs and LRs were searched against a large comprehensive
repository of vesicle data known as Vesiclepedia.95,96 From the 310,649 proteins within the vesicle
database we identified only 5 proteins from our dataset, these were: OCT, malate dehydrogenase,
vesicle-fusing ATPase, leucine-rich repeat protein 2 and midasin. From these five identifications
only OCT, malate dehydrogenase, vesicle-fusing ATPase were present in the vesicle fractions. The
low protein matches from Giardia suggests that there is a need for improvement in these
repositories and the mechanisms for vesicle secretion and their respective contents is a topic that
we can continue exploring.
Tenascins in particular have been discovered to be the involved in the degradation of the
epithelia and tight junctions as well as being found as a secreted component in giardial cells.104,111
When we look at the EVs, there is an interplay between lipid rafts and their necessity for the
secretion.41,112 In Figure 5.4 and supplement 4 we see that there are many of these virulence
factors are found both in LR and EVs. However the mechanisms of the blebbing of microvesicle
and exosome needs to be studied further since common secretory pathways like the ESCRT are
not fully present in Giardia.49 There may be a homologs or “moonlighting” proteins that may carry
out these functions.48,49 Following differential centrifugation methods we were able to isolate the
LRs and EVs before and after treatment to glimpse into protein modulators that were being altered.
Giardia is known to secret both large (ectosomes) and small (exosomes) EVs containing VSPs,
giardins91 and previously mentioned virulence factors found in the raw secretome.104 Additionally,
EVs are also necessary for interacting with host cells.91 The most drastic proteomic changes that
can be seen after treatment with LR disruptors in this study are VSPs, HCMPs, giardins, AMEs
and EF1 that were found primarily in the exosomes. Alterations in the LR and ectosomes virulence
factors also occurred but to a much smaller degree. Attempts have been made to discover the
possible connection and interplay between exosome biogenesis and LRs. In recent years, many
80

mechanism of endocytosis and exocytosis have been elucidated that is found to be both ESCRT
dependent and independent.34,37,113 There is a wide arrange of cellular endocytosis pathways such
as clathrin-dependent and -independent pathway as in micropinocytosis and phagocytosis,114–116
surface binding,117–121 membrane fusion122 and most interestingly LR-mediated endocytosis as
well as caveolae pathway.123–126 Since there are sufficient numbers of differentially expressed
proteins with exosomes in the future the focus should be given on the biogenesis and function of
these small vesicles. Exosomes are generated from the invagination of late endosomal membranes
resulting in intraluminal vesicles which mature to Multivesicular Bodies (MVBs) that can then
bind to the membrane and release its cargo of exosomes.127 During this process there has been
evidence to show that disruption of the ceramide or cholesterol synthesis can alter the exosome
composition by decreasing common exosome marker like flotillin and decreasing EGFR in both
the MVBs and exosomes.128 This process is appears to need Rab31 which is recruited in cholesterol
and ceramide rich membranes while interacting with flotillins and induce EGFR packing.128,129
Alternative pathways may exist such as MAP1LC3B (LC3) which is a mediator in ceramide
induced ILV formation.130
Drug repurposing is the concept of using compounds that are FDA approved or on
“market” for a different purpose or disease then the originally intended.131 Due to the slow and
expensive pace of novel drug discovery, repurposing of “old” drugs has become increasingly
popular since they have a lower risk/toxicity associated132with them and can potentially be
recommended for other diseases. Metronidazole resistant Giardia is an increasing problem and
alternative compounds to treat giardiasis are needed.133 Oseltamivir (Tamiflu®, anti-H1N1 flu)
inhibited encystation and cyst production in culture. It also drastically disrupted the membrane,
altered vesicle sizes, and changed the overall proteomic composition of EVs compared to the
control. The application in mouse models allowed us to assess if this compound could truly be
effective in reducing parasitic load treat giardiasis, and its effectiveness in compared to
metronidazole. Mice were infected with luciferase expressing giardia and infection was tracked
with the assistance of an In Vivo Imaging System (IVIS). Figure 4.1 shows the overall average
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radiance that was acquired per group. Oseltamivir given at 3 mg/kg shows a significant decrease
in the amount of luciferase expression compared to the control and comparatively as low as
Metronidazole. SP or SP1568, a derivative of oseltamivir matches the overall decrease in parasite
load compared to the control. This is impactful not only because it decreases the parasitemia load
but SP1568 may have a lower bioavailability and would not be absorbed as readily as oseltamivir,
allowing for an increased exposure of the compound to the trophozoites. Figure 4.2 like Figure
4.1 shows the same evidence and reproducibility of the treatment.
In Figure 4.3, we measured the overall number of cysts in the mouse fecal material,
indicative of Giardia infection and transmission. Oseltamivir at 1.5 mg/kg faired significantly
better than the control showing a sharp decrease during peak infection at day 13. Oseltamivir at
3.0 mg/kg reduced the total amount cysts to almost 0. This is comparable to our positive control
Metronidazole which was used at 3 mg/kg as well. This demonstrates the overall efficacy of
oseltamivir and appears to match that of Metronidazole and could be a potential candidate to treat
giardiasis. Theoretical scaling to human patients is the end goal of the project. Mice compared to
humans have an overall different rate metabolism and the concentration would obviously differ
between the two. There is however literature that suggest particular formulas to that convert animal
doses to human-equivalent doses (HEDs) based of body surface.134 On the basis of these formulas,
it is possible to calculate that the equivalence dosing for humans using the 3 mg/kg in mice as a
reference would be about 240mg. Common dosages for oseltamivir can range from 30 mg, 45 mg,
or 75 mg.135 If we take a 75mg dosing in a 70kg human, our current dosing is about two times
lower than the higher end dosing used for influenza using Sharma et. al. reference134 and three
times lower than plasma concentration in humans taking a 75 mg dose compared to plasma
concentration in mice taking a 10 mg/kg does.136 Overall, oseltamivir is efficient against giardiasis
in low concentrations compared to current dosing for influenza treatment.
Our results suggest that oseltamivir is effective in blocking the infection of Giardia and it
is comparable with metronidazole (Mtz). This suggests that oseltamivir, which targets raft
assembly and alters the parameters of released vesicles, demonstrates anti-giardial affects. On the
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other hand, Mtz targets thioredoxin reductase enzyme, which is not related to the assembly of rafts
and EVs.137 Therefore, it is likely that oseltamivir will be effective against Mtz-resistant cell lines.
Our future goal will be to assess oseltamivir and other analogues on MtZ-resistant Giardia. We
show that oseltamivir, which inhibits raft assembly and interferes with secretion of vesicles is
effective in reducing Giardia infection in mice, indicating that they are novel targets to develop
anti-giardial therapies in the future.
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Appendix

Supplementary 1: Percent Inhibition of Compounds on in vitro encystation. 1 x 10^6
trophozoites were grown in 4mL glass tubes with screw cap lids. Various compounds were
added to the tubes at different concentrations and tubes were incubated for 24 hours. The next
day, encystation medium supplemented with 10% adult bovine serum and 5 mg/ml bovine bile
was placed in the tubes along with additional doses of the compounds, then the tubes were
incubated for another 24 h. Water resistant cysts were collected and counted on a
hemocytometer. Percent of inhibition was calculated for Metronidazole, Oseltamivir and its
derivative.
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Supplement 2: Proteins and Peptides Identified Per Group and Treatment. Panel A shows the
proteins were quantified per samples between LR, LV and SV as well as between treatments. Panel
B shows the overall number of peptides that were quantified with the same comparisons as panel
A.

Supplement 3: Proteins that match the Vesiclepedia Repository
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Supplementary 4: Proteins shared between groups represented in Venn diagram

LR and LV

LR and LV (cont)

LV,SV and LR

LR and SV

14-3-3 protein

Median body protein

40S ribosomal protein S21

26S proteasome
ATPase subunit
S4, putative

40S ribosomal protein S3a

Methionine
aminopeptidase 2 (MAP
2) (MetAP 2) (EC
3.4.11.18) (Peptidase M)

40S ribosomal protein S30

Calmodulinbinding protein

40S ribosomal protein S4

Mitogen-activated
protein kinase (EC
2.7.11.24)

4-methyl-5-thiazole
monophosphate
biosynthesis enzyme
(Protein deglycase)

Cathepsin B (EC
3.4.22.1)

60S ribosomal protein L27

Coiled-coil protein

60S ribosomal protein L7a

Cyst wall protein 1

40S ribosomal protein S6
40S ribosomal protein S7

Mitotic spindle
checkpoint component
MAD2
Mitotic spindle
checkpoint protein MAD2

40S ribosomal protein S7
(Fragment)

NAD(P)H oxidoreductase

Adenine
phosphoribosyltransferase

40S ribosomal protein S8

NADH oxidase (Fragment)

Alpha-11 giardin

40S ribosomal protein SA
4-alpha-glucanotransferase,
amylo-alpha-1,6-glucosidase
4-alpha-glucanotransferase,
amylo-alpha-1,6-glucosidase
(EC 2.4.1.25) (EC 3.2.1.33)
(Amylo-alpha-1,6-glucosidase)
60S acidic ribosomal protein
P0

60S ribosomal protein L18a

NADH oxidase lateral
transfer candidate
NADP glutamate
dehydrogenase
(Fragment)
NADPH oxidoreductase,
putative
NADPH oxidoreductase,
putative (Putative NADPH
oxidoreductase)
NADP-specific glutamate
dehydrogenase (NADPGDH) (EC 1.4.1.4) (NADPdependent glutamate
dehydrogenase)

Alpha-7.1 giardin
Alpha-7.2 giardin

Endoribonuclease
L-PSP

Alpha-7.3 giardin

FixW protein,
putative

Ankyrin repeat protein 1
(Protein 21.1)

Heat shock factor
binding protein

Arginine deiminase

High cysteine
membrane
protein (VSP,
putative)

AAA family ATPase

Nitroreductase Fd-NR2

Arginine deiminase (EC
3.5.3.6)

ABC transporter family protein

Nuclear transport factor 2

A-type flavoprotein lateral
transfer candidate
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Cysteinyl-tRNA
synthetase (EC
6.1.1.16)
Dynein heavy
chain
Dynein light chain
roadblock

High cysteine
membrane
protein Group 1
High cysteine
membrane
protein Group 4

LR and LV

LR and LV (cont)

LV,SV and LR

LR and SV

Acetyl-CoA synthetase

Nucleoside hydrolase

A-type flavoprotein lateral
transfer candidate
(Flavoprotein)

Kinase, NEK

Beta giardin (Fragment)

Midasin

Beta-giardin (Fragment)

Prefoldin subunit

Actin related protein
Acyl-CoA synthetase
ADP-ribosylation factor
Alanine aminotransferase,
putative (Putative Alanine
aminotransferase)
Alcohol dehydrogenase 2 (EC
1.1.1.1)
Alcohol dehydrogenase 3
(Alcohol dehydrogenase
lateral transfer candidate)
Alcohol dehydrogenase lateral
transfer candidate

Ornithine cyclodeaminase
(EC 4.3.1.12)
Peptidylprolyl isomerase
(EC 5.2.1.8)
Phosphatidylinositol
transfer protein alpha
isoform
Phosphatidylinositol-4phosphate 5-kinase,
putative
Phosphoenolpyruvate
carboxykinase (GTP) (EC
4.1.1.32)
Phosphoglucomutase
(Phosphomannomutase2)
Phosphoglycerate mutase
(2,3-diphosphoglycerateindependent) (EC
5.4.2.12)

Calmodulin

Carbamate kinase

CCT-alpha (T-complex
protein 1 subunit alpha)

Chromosome segregation
protein SMC

Coiled-coil protein

Putative 26S
proteasome
regulatory subunit
Serine protease
inhibitor-like
protein
Thiol disulfide
oxidoreductase,
DsbA family
protein
(Fragment)
Ubiquitin-related
modifier 1
homolog
Uncharacterized
protein

Aldehyde-alcohol
dehydrogenase

Phospholipid-binding
Copine Family Protein

Cystatin

Aldose reductase

Phosphopyruvate
hydratase (EC 4.2.1.11)

Cytochrome b5-like
Heme/Steroid binding
domain-containing protein

Uncharacterized
protein
(Fragment)
Vacuolar ATP
synthase subunit
G

Aldose reductase (EC 1.1.1.21)

Polyadenylate-binding
protein, putative
(Putative Polyadenylatebinding protein)

Cytosolic HSP70 (Cytosolic
heat shock protein 70)

Variant-specific
surface protein

Alpha-1 giardin

Prefoldin subunit 3

Deflagellation inducible
protein (Sjogren's
syndrome nuclear
autoantigen 1-like protein)

Variant-specific
surface protein
(Fragment)

Alpha-1,4 glucan
phosphorylase (EC 2.4.1.1)

Prolyl-tRNA synthetase
(EC 6.1.1.15)

Delta giardin

Alpha-14 giardin

Proteasome component
c3

Dynein light chain
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Variant-specific
surface protein
1267
Variant-specific
surface protein
AS4 (Variantspecific surface
protein S1)

LR and LV

LR and LV (cont)

LV,SV and LR

LR and SV

Alpha1-giardin

Proteasome component
pre5

Elongation factor 1-alpha
(EF-1-alpha) (14 nm
filament-associated
protein) (Fragment)

Variant-specific
surface protein
VSP9B10

Elongation factor 1-alpha
(Fragment)

Variant-specific
surface protein
WB/9B10-B

Alpha-3 giardin
Alpha-6 giardin

Proteasome
endopeptidase complex
(EC 3.4.25.1)
Proteasome subunit
alpha type

Alpha-SNAP, putative

Protein 21.1

Alpha-SNAP, putative (Putative
Alpha-SNAP)

Aminoacyl-histidine
dipeptidase (EC 3.4.13.-)

Protein disulfide
isomerase
Protein disulfide
isomerase (Protein
disulfide isomerase PDI1)
Protein disulfide
isomerase PDI2

ANK_REP_REGION domaincontaining protein

Protein disulfide
isomerase PDI4

ANK_REP_REGION domaincontaining protein (Fragment)

Protein kinase, catalytic
domain

Aminoacyl-histidine
dipeptidase

Ankyrin repeat protein
Ankyrin repeat protein 1
Ankyrin repeat protein 1
(Protein 21.1)
Ankyrin repeat protein 3
(Protein 21.1)
AP complex subunit beta

ARF GAP

Arginyl-tRNA synthetase (EC
6.1.1.19)
Aspartyl-tRNA synthetase (EC
6.1.1.12)

Putative annexin repeat
protein
Putative p23-like domain
protein
Putative RNA binding
protein (RNA binding
protein, putative)
Putative Spindle pole
protein (Spindle pole
protein, putative)
Putative
transglutaminase-like
superfamily protein
Putative Translation
initiation factor eIF-4A
(Translation initiation
factor eIF-4A, putative)
Pyrophosphate--fructose
6-phosphate 1phosphotransferase
Pyruvate kinase (EC
2.7.1.40)
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Eukaryotic translation
initiation factor 5A (eIF-5A)
FixW protein, putative
(Putative FixW protein)
Fructose-bisphosphate
aldolase

VSP (VSP with INR)

Gamma giardin protein
(Giardin gamma chain)

VSP with INR

Giardia trophozoite antigen
GTA-1
Glyceraldehyde-3phosphate dehydrogenase
(EC 1.2.1.12)
Glyceraldehyde-3phosphate dehydrogenase
1 (GAPDH) (EC 1.2.1.12)
GTP-binding nuclear
protein
Heat shock protein 70
(Fragment)
Histone H2A

Histone H2B
H-SHIPPO 1 (SHIPPO repeat
domain-containing protein)
Hybrid cluster protein
(Hybrid cluster protein
lateral transfer candidate)
Kinase, NEK
LSU ribosomal protein L11P
(Fragment)

VSP

VSP AS8

LR and LV

LR and LV (cont)

LV,SV and LR

Assemblin/beta giardin family
protein (SALP-1)
ATP/GTP binding protein,
putative (Putative ATP/GTP
binding protein)
ATPase involved in DNA
repair/chromosome
segregation

Pyruvate, phosphate
dikinase (EC 2.7.9.1)

Macrophage migration
inhibitory factor

Pyruvate:ferredoxin
oxidoreductase

Mucin-like protein

Pyruvate-flavodoxin
oxidoreductase

NAC domain-containing
protein

Pyruvate-flavodoxin
oxidoreductase (EC 1.-.-.-)

NAC-A/B domaincontaining protein

Qb-SNARE 1

Nucleoside diphosphate
kinase (EC 2.7.4.6)

ATP-binding cassette protein 5
ATP-dependent carboxylateamine ligase, ATP-grasp
domain protein
ATP-dependent RNA helicase
p47, putative

Ribokinase (EC 2.7.1.15)
(Fragment)

ATP-dependent RNA helicaselike protein

Ribokinase (RK) (EC
2.7.1.15)

Axoneme central apparatus
protein
Axoneme-associated protein
GASP-180
Axoneme-associated protein
GASP-180 (Fragment)
Beta adaptin
Branched-chain amino acid
aminotransferase

Ribosomal protein L10a
Ribosomal protein L13
Ribosomal protein L14
Ribosomal protein L15
Ribosomal protein L18

CCT-epsilon (T-complex
protein 1 subunit epsilon)

Ribosomal protein L21

CCT-theta

Ribosomal protein L23

CCT-theta (Fragment)

Ribosomal protein L24A

CDP-diacylglycerol--glycerol-3phosphate 3phosphatidyltransferase
Centrin (Putative calciumbinding family protein)
Chaperone protein dnaJ
Chaperonin subunit zeta
CCTzeta
Chromosome segregation
protein SMC
CoA-disulfide reductase
NAD(P)H

Ornithine
carbamoyltransferase
Peptidyl-prolyl cis-trans
isomerase (PPIase) (EC
5.2.1.8)
Peptidylprolyl isomerase
(EC 5.2.1.8)
Peroxiredoxin 1 (EC 1.11.1.)
Phosphoglycerate kinase
(EC 2.7.2.3)
Prefoldin subunit 2
Protein disulfide isomerase
(Fragment)
Protein Translation
Elongation Factor 1A (EF1A) (Fragment)
Putative purine nucleoside
phosphorylase (UPL-1)
Putative Spindle pole
protein (Spindle pole
protein, putative)

Ribosomal protein L26

Putative_PNPOx domaincontaining protein

Ribosomal protein L27a

RAN binding protein 1

Ribosomal protein L29

Rhodanese-like protein

Ribosomal protein L3

Ribosomal L38e

Ribosomal protein L35a

Ribosomal protein L23A

Ribosomal protein L36-1
(Ribosomal protein L36e)

Ribosomal protein L31B
(Ribosomal protein L31e)
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LR and LV

LR and LV (cont)

LV,SV and LR

Coiled-coil protein
Cytidine deaminase (EC
3.5.4.5) (Cytidine
aminohydrolase)

Ribosomal protein L4

Ribosomal protein P2

Ribosomal protein L5

Ribosomal protein S28

DEAD box RNA helicase Vasa

Ribosomal protein L7

DEAD-box helicase family
protein
Deoxyhypusine synthase,
putative (EC 2.5.1.46)
(Putative Deoxyhypusine
synthase)
Dipeptidyl aminopeptidase III
(EC 3.4.14.4) (Dipeptidyl
peptidase III) (Fragment)
Dipeptidyl peptidase 3 (EC
3.4.14.4) (Dipeptidyl
aminopeptidase III) (Dipeptidyl
peptidase III)
Disc-associated protein
DUF1681 domain-containing
protein
Dynamin GTPase

Ribosomal protein L9

Ribosomal protein P1B

Stress-inducedphosphoprotein 1

Ribosomal protein S13

Thioredoxin

Ribosomal protein S14

Thioredoxin domaincontaining protein

Ribosomal protein S15
Ribosomal protein S15A
Ribosomal protein S16

Dynamin GTPase (Dynaminlike protein)

Ribosomal protein S18

Dynein heavy chain

Ribosomal protein S19e

EGF family protein

Ribosomal protein S2

Elongation factor 1 beta,
guanine nucleotide exchange
domain protein
Elongation factor 1-gamma

RNA recognition motifcontaining protein
Spindle pole protein,
putative

Thioredoxin peroxidase
(Fragment)
Thioredoxin reductase (EC
1.8.1.9)
Thioredoxin-like protein
Translation elongation
factor (Translation
elongation factor 1-beta)
Translation initiation
inhibitor
Triosephosphate isomerase
(EC 5.3.1.1) (Fragment)

Ribosomal protein S23

Tubulin alpha chain

Ribosomal protein S24

Tubulin beta chain
Tubulin-specific chaperone
A

Elongation factor 2

Ribosomal protein S5

Endonuclease III homolog

RNA recognition motif
family protein

Ubiquitin

RNase L inhibitor

Uncharacterized protein

RuvB-like helicase (EC
3.6.4.12)

Uncharacterized protein
(Fragment)

Ser/Thr phosphatase 2A
regulatory subunit A
(Ser/Thr phosphatase 2A,
65kDa reg sub A)

UVR domain-containing
protein

Enkurin domain-containing
protein
FAD dependent
oxidoreductase
FAD/FMN dependent
oxidoreductase (NADH
oxidase) (EC 1.-.-.-)
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LR and LV
FAD-dependent glycerol-3phosphate dehydrogenase
(Glycerol-3-phosphate
dehydrogenase) (EC 1.1.5.3)
Flagellar exit site protein
(p115, putative)
FYVE zinc finger domaincontaining protein
FYVE-type domain-containing
protein
Giardin subunit alpha-2
Glucokinase+A118AA93:A245
Glucokinase (EC 2.7.1.2)
Glucose-6-phosphate
isomerase (EC 5.3.1.9)
Glutamate dehydrogenase
(Fragment)
Glutamate synthase
Glutamine-tRNA synthetase
(Glutaminyl-tRNA synthetase)
(EC 6.1.1.18)
H(+)-transporting two-sector
ATPase (EC 7.1.2.2)
Heat shock protein 90
Heat shock protein HSP 90alpha
Heat-shock protein, putative
Heat-shock protein, putative
(Putative Heat-shock protein)
Histone H4
H-SHIPPO 1 (SHIPPO repeat
domain-containing protein)
Importin beta-3 subunit

LR and LV (cont)

LV,SV and LR

Ser/Thr protein kinase

Variant-specific surface
protein (Fragment)

Serine/threonine protein
kinase
Serine/threonine protein
phosphatase 7
Serine/threonine-protein
phosphatase (EC 3.1.3.16)
Seryl-tRNA synthetase (EC
6.1.1.11)
Small glutamine-rich
tetratricopeptide repeatcontaining protein
Spindle pole protein,
putative
SSU ribosomal protein
S10P
SSU ribosomal protein
S12E
SSU ribosomal protein
S12P
SSU ribosomal protein
S17E
SSU ribosomal protein
S17P
SSU ribosomal protein
S19E (Fragment)
SSU ribosomal protein
S3P
SSU ribosomal protein
S4P
START domain-containing
protein
Superfamily II DNA and
RNA helicase
T-complex protein 1
subunit eta (TCP-1-eta)
(CCT-eta)
T-complex protein 1
subunit gamma

Kelch repeat-containing
protein

Tctex-1 family protein

Kinase, NEK

Thioredoxin peroxidase
(Fragment)
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Vesicle-fusing ATPase (EC
3.6.4.6)
VSP
VSP (VSP with INR)
VSP with INR

LR and LV

LR and LV (cont)

Kinase, NEK (Kinase, NEK-frag)
Kinesin motor domain protein

Threonine dehydratase
Transketolase (EC 2.2.1.1)
Translation initiation
factor eIF-4A, putative

Kinesin-3
Lecithin-cholesterol acyl
transferase, putative (Putative
Lecithin-cholesterol acyl
transferase)
Lipopolysaccharide-responsive
and beige-like anchor protein
LSU ribosomal protein L10AE
LSU ribosomal protein L15P
LSU ribosomal protein L19E
LSU ribosomal protein L2P
LSU ribosomal protein L30E
LSU ribosomal protein L34E
LSU ribosomal protein L35AE
LSU ribosomal protein L3P
LSU ribosomal protein L4/L1
family protein
LSU ribosomal protein L5P
LSU ribosomal protein L6P
LSU ribosomal protein L7
LSU ribosomal protein,
L18p/L5e family (Ribosomal
protein L5)
Malate dehydrogenase (EC
1.1.1.37)
Malate dehydrogenase (Malic
enzyme)

Trophozoite antigen GTA2
Tubulin alpha chain
(Fragment)
Tubulin beta chain
(Fragment)
Ubiquitin-like protein
UMP pyrophosphorylase
(EC 2.4.2.9)
Uncharacterized protein
Uncharacterized protein
(Fragment)
Uridine kinase (EC
2.7.1.48)
Vacuolar ATP synthase E
subunit
Vacuolar ATP synthase
subunit B (EC 3.6.3.14)
Vacuolar protein sorting
35
Vacuolar protein
sorting/targeting protein
VPS26
Variant-specific surface
protein
Vesicle-fusing ATPase (EC
3.6.4.6)
Viral A-type inclusion
protein repeat protein
Wos2 protein
Xaa-Pro dipeptidase
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